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A B S T R A C T
Background
Venous thromboembolism (VTE) is a prevalent and serious condition. Itsmedical treatment requires anticoagulation, usually with either
unfractionated or low molecular weight heparin (LMWH). Administration of unfractionated heparin (UFH) is usually intravenous
(IV) but can be subcutaneous as well. This is an update of a review ﬁrst published in 2009.
Objectives
To assess the effects of subcutaneous UFH versus intravenous UFH, subcutaneous LMWH or any other anticoagulant drug for the
initial treatment of venous thromboembolism.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Specialised Register (last searched 30 November 2016)
and CENTRAL (2016, Issue 10). The Cochrane Vascular Information Specialist also searched trials registries for details of ongoing or
unpublished studies.
Selection criteria
Randomised controlled trials comparing subcutaneous UFH to control, such as subcutaneous LMWH, continuous intravenous UFH
or other anticoagulant drugs in participants with acute venous thromboembolism.
Data collection and analysis
Two review authors (JS and LR) independently extracted data and assessed the risk of bias in the trials. We used meta-analyses when
we considered heterogeneity low. The primary outcomes were symptomatic recurrent venous thromboembolism (deep vein thrombosis
and/or pulmonary embolism), VTE-related mortality, adverse effects of treatment including major bleeding, and all-cause mortality.
We calculated all outcomes using an odds ratio (OR) with a 95% conﬁdence interval (CI).
Main results
We included one additional study in this update, bringing the total number of studies in the review to 16 randomised controlled trials,
with a total of 3593 participants (1745 participants in the intervention group and 1848 participants in the control group). Eight trials
used intravenous UFH as the control treatment, seven trials used LMWH, and one trial had three arms with both drugs as the controls.
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We did not identify trials comparing subcutaneous UFH with other anticoagulant drugs. We downgraded the quality of the evidence
to low due to lack of blinding in studies, which led to a risk of performance bias, and also for imprecision, as reﬂected by the wide
conﬁdence intervals.
When comparing subcutaneous versus IV UFH, there was no difference in the incidence of symptomatic recurrent VTE at three
months (odds ratio (OR) 1.66, 95% conﬁdence interval (CI) 0.89 to 3.10; 8 studies; N = 965; low-quality evidence), symptomatic
recurrent deep vein thrombosis (DVT) at three months (OR 3.29, 95% CI 0.64 to 17.06; 1 study; N = 115; low-quality evidence),
pulmonary embolism (PE) at three months (OR 1.44, 95% CI 0.73 to 2.84; 9 studies; N = 1161; low-quality evidence), VTE-related
mortality at three months (OR 0.98, 95% CI 0.20 to 4.88; 9 studies; N = 1168; low-quality evidence), major bleeding (OR 0.91,
95% CI 0.42 to 1.97; 4 studies; N = 583; low-quality evidence) or all-cause mortality (OR 1.74, 95% CI 0.67 to 4.51; 8 studies; N
= 972; low-quality evidence). There were no episodes of asymptomatic VTE occurring within three months of the commencement of
treatment.
When comparing subcutaneous UFH versus LMWH, there was no difference in the incidence of recurrent VTE at three months (OR
1.01, 95% CI 0.63 to 1.63; 5 studies; N = 2156; low-quality evidence), recurrent DVT at three months (OR 1.38, 95% CI 0.73 to
2.63; 3 studies; N = 1566; low-quality evidence), PE (OR 0.84, 95% CI 0.36 to 1.96; 5 studies, N = 1819; low-quality evidence),
VTE-related mortality (OR 0.53, 95% CI 0.17 to 1.67; 8 studies; N = 2469; low-quality evidence), major bleeding (OR 0.72, 95%
CI 0.43 to 1.20; 5 studies; N = 2300; low-quality evidence) or all-cause mortality (OR 0.73, 95% CI 0.50 to 1.07; 7 studies; N =
2272; low-quality evidence). There were no episodes of asymptomatic VTE occurring within three months of the commencement of
treatment.
Authors’ conclusions
There is no evidence of a difference between subcutaneous versus intravenous UFH for preventing VTE recurrence, VTE-related or
all-cause mortality, and major bleeding. According to GRADE criteria, the quality of the evidence was low. There is also no evidence
of a difference between subcutaneous UFH and LMWH for preventing VTE recurrence, VTE-related or all-cause mortality or major
bleeding.
P L A I N L A N G U A G E S U M M A R Y
Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Background
Venous thromboembolism (VTE) is a condition where a blood clot forms in the deep veins (most commonly of the leg) and can travel
up to block the arteries in the lungs (a life-threatening condition known as pulmonary embolism). Treating VTE requires injections of a
drug called heparin, which stops further clots forming. Heparin comes in two forms: unfractionated heparin (UFH) and low molecular
weight heparin (LMWH). UFH can be administered as a continuous intravenous (IV) infusion or intermittently as an injection under
the skin (subcutaneous), while LMWH is injected subcutaneously. This review measures the effects of subcutaneous UFH versus IV
UFH and LMWH for preventing recurrent clots, mortality and major bleeding. This is an update of a review published in 2009.
Key results
After searching for relevant studies up toNovember 2016, we found one study to add to this update. In total, we included 16 randomised
controlled trials in 3593 participants in this review. This update showed that there was no evidence of a difference between subcutaneous
UFH versus intravenous UFH or subcutaneous LMWH for preventing recurrent clots, death or major bleeding.
Quality of the evidence
The quality of the evidence was low due to lack of blinding in the included studies and imprecision of the results due to the small
number of reported events.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Subcutaneous unfractionated heparin compared to intravenous unfractionated heparin for the initial treatment of venous thromboembolism
Patient or population: people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Setting: inpat ient and outpat ient
Intervention: subcutaneous unf ract ionated heparin
Comparison: intravenous unf ract ionated heparin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Risk with intravenous un-
fractionated heparin
Risk with subcutaneous un-
fractionated heparin
Symptomatic recurrent VTE
at 3 months
Study populat ion OR 1.66
(0.89 to 3.10)
965
(8 RCTs)
⊕⊕©©
Lowa
35 per 1000 57 per 1000
(32 to 102)
Symptomatic recurrent DVT
at 3 months
Study populat ion OR 3.29
(0.64 to 17.06)
115
(1 RCT)
⊕⊕©©
Lowb
34 per 1000 105 per 1000
(22 to 379)
PE at 3 months Study populat ion OR 1.44
(0.73 to 2.84)
1161
(9 RCTs)
⊕⊕©©
Lowc
26 per 1000 37 per 1000
(19 to 70)
VTE-related mortality at 3
months
Study populat ion OR 0.98
(0.20 to 4.88)
1168
(9 RCTs)
⊕⊕©©
Lowc
3 per 1000 3 per 1000
(1 to 17)
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Major bleedingd
(7 days - 12 months)
Study populat ion OR 0.91
(0.42 to 1.97)
583
(4 RCTs)
⊕⊕©©
Lowe
48 per 1000 44 per 1000
(21 to 91)
All-cause mortality
(5 days to 12 months)
Study populat ion OR 1.74
(0.67 to 4.51)
972
(8 RCTs)
⊕⊕©©
Lowa
12 per 1000 21 per 1000
(8 to 54)
Asymptomatic VTE at 3
months
No study measured this outcome
* The basis for the assumed risk was the average risk in the intravenous unf ract ionated heparin group (i.e. the number of part icipants with events divided by total number of
part icipants of the intravenous heparin group included in the meta-analysis). The risk in the subcutaneous unfractionated heparin group (and its 95% conf idence interval) is
based on the assumed risk in the intravenous unf ract ionated heparin group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT : deep vein thrombosis; PE: pulmonary embolism; RCT : randomised controlled trial; OR: odds rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the quality of the evidence to low due to a high risk of performance bias in eight studies (Andersson
1982; Belcaro 1999; Bent ley 1980; Doyle 1987; Krähenbühl 1979; Lopaciuk 1990; Pini 1990; Walker 1987), plus a high
risk of attrit ion bias in f ive studies (Andersson 1982; Belcaro 1999; Bent ley 1980; Krähenbühl 1979; Pini 1990). We also
downgraded for imprecision, as ref lected by the wide conf idence intervals.
bWe downgraded the quality of the evidence to low for imprecision as only one study with a small number of part icipants was
included, leading to a wide conf idence interval around the ef fect est imate (Hull 1986).
cWe downgraded the quality of the evidence to low due to a high risk of performance bias in seven studies (Andersson 1982;
Bent ley 1980; Doyle 1987; Krähenbühl 1979; Lopaciuk 1990; Pini 1990; Walker 1987), plus a high risk of attrit ion bias in four
studies (Andersson 1982; Bent ley 1980; Krähenbühl 1979; Pini 1990). We also downgraded for imprecision ref lected by the
wide conf idence intervals.
d Major bleeding as def ined by the Internat ional Society on Thrombosis and Haemostasis (ISTH) (Schulman 2005); fatal
bleeding; symptomatic bleeding in a crit ical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-
art icular or pericardial, or intramuscular with compartment syndrome; bleeding causing a fall in haemoglobin level of 20 g/
4
S
u
b
c
u
ta
n
e
o
u
s
u
n
fra
c
tio
n
a
te
d
h
e
p
a
rin
fo
r
th
e
in
itia
l
tre
a
tm
e
n
t
o
f
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
L (1.24 mmol/ L) or more, or leading to transfusion of two or more units of whole blood or red cells; any combinat ion of the
above.
eWe downgraded the quality of the evidence to low due to a high risk of performance bias in three studies (Doyle 1987;
Lopaciuk 1990; Pini 1990), plus a high risk of attrit ion bias in one study (Pini 1990). We also downgraded for imprecision, as
ref lected by the wide conf idence intervals.
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B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE) describes the formation of
thrombus in the deep veins, most commonly in the legs (deep vein
thrombosis, or DVT). VTE may also refer to the subsequent em-
bolisation of all or part of the thrombus to the pulmonary circula-
tion (pulmonary embolism, or PE). DVT of the lower limbs may
be associated with localised pain, swelling and erythema as well as
the development of pulmonary emboli and the later occurrence
of post-thrombotic syndrome (persistent swelling, erythema and
ulceration). PE presents acutely with shortness of breath, pain on
inspiration, tachycardia and right heart overload, and if untreated,
it can lead to chronic thromboembolic pulmonary hypertension,
acute circulatory collapse and death. Increasingly, in the era of
more liberal central venous catheterisation, DVT may involve the
upper extremities. Rarely, it may also affect other venous circula-
tion (cerebral veins, portal and mesenteric veins, etc.).
In addition to DVT and PE, thrombus can also form in the super-
ﬁcial veins, where it is associated with local pain and inﬂammation
(superﬁcial venous thrombosis). This tends to be associated with
lower mortality and morbidity rates than DVT, although some
patients may be at a higher risk of DVT formation depending on
the location of the clot (Chengelis 1996; Nasr 2015).
Venous thromboembolism (VTE) is comprised of DVT and PE
and can occur spontaneously. However, there are many risk fac-
tors for VTE, including periods of inactivity, dehydration, hos-
pitalisation, trauma, clotting disorders and previous thrombosis,
varicose veins with phlebitis, pregnancy, oral combined hormonal
contraceptives, malignancy, obesity, smoking, and age (Anderson
2003; NICE 2010).
The incidence of VTE in mostly white populations is between
100 and 200 per 100,000 person-years (Heit 2015; White 2003).
Of these, it is estimated that 45 to 117 cases per 100,000 person-
years are due to DVT (without PE), and 29 to 78 are due to PE
(with or without DVT) (Heit 2015). Recurrent VTE occurs in
approximately 7.4% of patients at 1 year and up to 30.4% of
patients by 10 years (Cushman 2007; Heit 2015; White 2003).
Description of the intervention
Heparin is a heterogeneous mixture of branched glycosaminogly-
cans (GAG), discovered in 1916 (McLean 1916).
The anticoagulant action of heparin requires the binding of an-
tithrombin (AT). Heparin binds to AT through a unique glu-
cosamine unit that is contained within a pentasaccharide sequence
present in a fraction of the GAGmolecules. Currently, three ther-
apeutic heparin preparations are available for clinical use: un-
fractionated heparin (UFH) with a molecular weight of approx-
imately 15,000 daltons; its derivative low molecular weight hep-
arin (LMWH), with an average molecular weight of 4000 to 5000
daltons; and the signiﬁcantly more expensive pentasaccharide. Al-
though LMWH has largely replaced UFH in the setting of acute
VTE treatment, many people do not beneﬁt from its use due to
increased risk of complications, speciﬁcally bleeding in patients
with severe renal failure.
How the intervention might work
Complications of heparin use may include bleeding; heparin-in-
duced thrombocytopenia (HIT); and in the long term, heparin-
induced osteoporosis. Consequently, it is important to monitor
coagulation factors, speciﬁcally the activated partial thromboplas-
tin time (aPTT), when usingUFH.There are two preferredmodes
of administering this treatment: a continuous intravenous (IV)
mode and an intermittent subcutaneous mode. Depending on the
method chosen, pharmacokinetic analyses demonstrate differences
in heparin bioavailability and early achievement of a therapeutic
aPTT goal, favouring the intravenous route (Hull 1986).
Nevertheless, investigators have evaluated the subcutaneous route
of administration for VTE due to its ease of application, early
mobilisation and hospital discharge, and presumably less line-re-
lated complications. People have received the treatment either in
weight-adjusted or aPTT-adjusted doses, and investigators have
compared results with other available treatment modalities.
Why it is important to do this review
Two meta-analyses comparing LMWH versus intravenous UFH
have shown LMWH to be non-inferior to UFH with regards to
recurrent DVT, PE, bleeding and thrombocytopenia (reduction in
the number of platelets) (Dolovich 2000; Quinlan 2004). How-
ever, there were no trials utilising subcutaneous UFH for this in-
dication in these analyses. The present review was originally com-
pleted in 2009 (Vardi 2009), and an update is necessary to in-
corporate evidence from any new studies completed since then.
Additionally, Cochrane has developed new methodology during
that time that should be incorporated in the updated review.
O B J E C T I V E S
To assess the effects of subcutaneous UFH versus intravenous
UFH, subcutaneous LMWH or any other anticoagulant drug for
the initial treatment of venous thromboembolism.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials comparing the effects of subcuta-
neous UFH versus intravenous UFH, LMWH or any other an-
ticoagulant drug for the initial treatment of venous thromboem-
bolism. We included trials with more than two treatment groups
and analysed them accordingly. We did not expect to ﬁnd any
cross-over trials in the setting of VTE. We included trials with
interventions and follow-up periods of any duration.
We excluded randomised controlled trials without truly random
allocation to the treatment or control group or without allocation
concealment, in view of the fact that prior knowledge of treatment
allocation may have led to biased participant allocation, treatment
or reporting. After allocation, further concealment of treatment
may be impossible due to the differences between preparations and
routes of administration. Thus, despite recognising that this may
lead to biased treatment or reporting, post-allocation blinding was
not a prerequisite, and we addressed it in a sensitivity analysis.
We acknowledge that non-randomised studies or studies using
other randomisation methods (for example cluster randomisation)
may provide useful information about this problem. However, for
this review, we did not consider such studies.
Types of participants
Adults (aged 18 years or older) with a diagnosis of new or recurrent
VTE. Ideally, the diagnosis of DVT of the leg was made with the
use of compression ultrasonography, colour-coded duplex ultra-
sonography or contrast venography, and the diagnosis of PE with
high probability ventilation-perfusion scan or pulmonary arterial
ﬁlling defects on computed tomography or invasive angiography.
Types of interventions
Initial treatment with subcutaneous UFH for individuals with
VTE, administered at any regimen, in trials of any duration.
1. Subcutaneous UFH:
i) ﬁxed weight-adjusted dose;
ii) aPTT-adjusted dose.
2. Other treatment modalities:
i) intravenous UFH;
ii) subcutaneous LMWH;
iii) other.
We expected studies to administer supplementary treatment of
VTE with an oral anticoagulant titration. We considered its use
in a subgroup analysis.
Types of outcome measures
Primary outcomes
• Incidence of symptomatic recurrent VTE at three months
• Incidence of symptomatic recurrent DVT at three months
• PE at three months
• VTE-related mortality at three months
• Major bleeding (as deﬁned by the International Society on
Thrombosis and Haemostasis (ISTH) (Schulman 2005): fatal
bleeding; symptomatic bleeding in a critical area or organ, such
as intracranial, intraspinal, intraocular, retroperitoneal, intra-
articular or pericardial, or intramuscular with compartment
syndrome; bleeding causing a fall in haemoglobin level of 20 g/L
(1.24 mmol/L) or more, or leading to transfusion of two or more
units of whole blood or red cells; any combination of the above)
• All-cause mortality
Secondary outcomes
• Incidence of asymptomatic VTE at three months
• Treatment-related morbidity: minor bleeding (bleeding that
is clinically overt but not meeting the deﬁnition of serious
bleeding provided by the ISTH) and heparin-induced
thrombocytopenia
• Length of hospital stay
• Quality of life
Search methods for identification of studies
We did not restrict the search for eligible studies by language.
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials.
• Cochrane Vascular Specialised Register (30 November
2016).
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 10) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used for CEN-
TRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINEOvid, EmbaseOvid, CINAHL, AMED, and through hand-
searches of relevant journals. The full list of the databases, journals
and conference proceedings included in these searches, as well as
the search strategies used, are described in the Specialised Register
section of the Cochrane Vascular module in the Cochrane Library
(www.cochranelibrary.com).
The CIS searched the following trial registries for details of ongo-
ing and unpublished studies.
• ClinicalTrials.gov (www.clinicaltrials.gov).
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch).
• ISRCTN Register (www.isrctn.com/).
See Appendix 2 for details of the search strategies.
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Searching other resources
We handsearched the reference lists of relevant trials and reviews
identiﬁed for additional studies.
Data collection and analysis
Selection of studies
For this update, two review authors (JS, LR) independently
scanned the titles, abstracts and keywords of every record retrieved.
We retrieved full articles for further assessment if the information
given suggested that the study fulﬁlled the inclusion criteria and
did not meet the exclusion criteria. If there was any doubt regard-
ing these criteria based on the title and abstract, we retrieved the
full article for clariﬁcation.
Data extraction and management
For studies that fulﬁlled the inclusion criteria, we abstracted
relevant population and intervention characteristics using stan-
dard data extraction templates. For details, see Characteristics of
included studies and Appendix 3 (Additional study information).
We resolved disagreements by discussion.
For this update, two review authors (JS, LR) extracted the follow-
ing data.
1. General information: author, title, publication (published/
unpublished; duplicate/multiple publication), language of
publication, year of publication, country, complete reference or
source, contact details, rural or urban setting, single centre versus
multicentre, setting, stated aim of the study, sponsor, ethics
committee approval and description of conﬂict of interests.
2. Trial design: prospective study, control group, parallel
study, placebo controlled, active-medication controlled, use of
cross-over design (and if so, description of run-in period, wash-
out period and carry-over effect described), description of period
effect, sampling method and power calculation, selection bias
(randomisation, unit of randomisation and allocation
concealment adequacy), performance bias (blinding of
participants and caregivers, method of blinding, check of
blinding, check of blinding method), attrition bias (intention-to-
treat analysis, description of withdrawals, drop-outs description
and losses to follow-up, change of groups (if cross-overs),
number of dropouts and withdrawals and loss to follow-up,
reasons and description for dropouts, withdrawals or losses to
follow-up), and detection bias (blinding of outcome assessors),
overall quality assessment, deﬁnition of inclusion criteria,
deﬁnition of exclusion criteria„ and speciﬁed subgroups
(predeﬁned and deﬁned post hoc).
3. Participants: venous thromboembolism (VTE) diagnostic
criteria description, VTE diagnostic criteria validity„ baseline
characteristics (i.e. number of participants, age, sex, race, body
mass index, comorbidities, concomitant medications, identical
treatment of groups (apart from intervention)).
4. Intervention: dose adjustment for subcutaneous UFH
(weight-adjusted or aPTT-adjusted), bolus intravenous heparin
in subcutaneous arm, number of daily subcutaneous doses, daily
heparin cumulative dose, duration of heparin therapy (days),
warfarin dose, length of follow-up, compliance.
5. Outcomes assessed for short, intermediate and long
term as deﬁned above: incidence of symptomatic recurrent deep
vein thrombosis (DVT) or pulmonary embolism (PE), mortality
related to propagation of VTE, treatment-related mortality
during heparin treatment, incidence of asymptomatic
propagation of VTE, treatment-related morbidity during
heparin treatment (major bleeding, minor bleeding, heparin-
induced thrombocytopenia (HIT), other), length of hospital
stay, quality of life.
6. Effect modiﬁers: compliance, change of concomitant
medication, warfarin therapy.
We sought any relevant missing information on the trials from the
original author(s) of the article, if required.
Assessment of risk of bias in included studies
Two review authors (JS, LR) independently used the Cochrane
’Risk of bias’ tool to assess the risk of bias for each of the in-
cluded studies (Higgins 2011). The tool provides a protocol for
judgements on sequence generation, allocation methods, blinding
of participants, investigators and outcome assessors, incomplete
outcome data, selective outcome reporting and any other relevant
biases. We judged each of these domains as being at either high,
low or unclear risk of bias according to Higgins 2011 and pro-
vided support for each judgement, resolving any disagreements by
discussion. We present the conclusions in a ’Risk of bias’ table.
Measures of treatment effect
We based the analysis on intention-to-treat data from the individ-
ual clinical trials. For the primary and secondary outcomes, which
are binary measures, we computed odds ratios (ORs) using a ﬁxed-
effect model and calculated the 95% conﬁdence intervals (CI) of
the effect sizes. For the continuous outcomes such as length of hos-
pital stay and quality of life, we planned to use mean differences
(MDs) with 95% CIs where the scales were the same, and where
scales were different but the outcome was the same, we planned
to use the standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
The unit of analysis was the individual participant.
Dealing with missing data
We sought relevantmissing data from authors where necessary and
feasible. We carefully evaluated important numerical data such as
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screened, eligible and randomised participants as well as intention-
to-treat and per-protocol population. We investigated dropouts,
losses to follow-up and withdrawn study participants.
Assessment of heterogeneity
We assessed heterogeneity between the trials by visual examination
of the forest plot to check for overlapping CIs, the Chi2 test for
homogeneity with a 10% level of signiﬁcance and the I2 statistic
to measure the degree of inconsistency between the studies. An I2
result of greater than 50% may represent moderate to substantial
heterogeneity (Deeks 2011).
Assessment of reporting biases
We planned to assess publication bias by funnel plots if a sufﬁ-
cient number of studies (10 or more) were available in the meta-
analyses. There are many reasons for funnel plot asymmetry, and
we planned to consult the Cochrane Handbook for Systematic Re-
views of Interventions to aid the interpretation of the results (Sterne
2011).
Data synthesis
The review authors independently extracted the data. One review
author (LR) entered the data into Review Manager 5 (RevMan
2014), and the second review author (JS) cross-checked data en-
try. We resolved any discrepancies by consulting the source publi-
cation.
If data were available, sufﬁciently similar and of sufﬁcient quality,
we provided a statistical summary. We used a ﬁxed-effect model
to meta-analyse the data. If the I2 statistic indicated heterogeneity
greater than 50%, we performed a random-effects model analysis
instead.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analyses, according to the fol-
lowing clinically logical pre-deﬁned groups.
1. Participants.
i) VTE at randomisation: DVT with/without PE versus
DVT without PE versus PE without DVT.
ii) VTE: ﬁrst versus recurrent.
iii) Severity: haemodynamically stable versus unstable,
respiratory stable versus unstable.
iv) Age.
v) Renal function.
vi) Underlying pathology (e.g. orthopaedic patients).
2. Intervention.
i) Number of daily subcutaneous heparin injections.
ii) Type of dose adjustment; weight-adjusted versus
aPTT-adjusted.
iii) Initial intravenous bolus heparin given versus not
given.
iv) Concomitant oral anticoagulant use.
v) Timing of oral anticoagulant initiation.
We performed neither a dose-response analysis nor any indirect
comparisons between groups not directly evaluated head-to-head
in a clinical trial.
Sensitivity analysis
We planned to perform sensitivity analyses in order to explore
the inﬂuence of the following factors on effect size, repeating the
analysis by:
• excluding data from unpublished studies;
• taking account of study quality, as speciﬁed above;
• excluding any very long or large studies to establish how
much they dominated the results;
• excluding studies using the following ﬁlters: diagnostic
criteria, language of publication, source of funding (industry
versus other), country.
Summary of findings table
Wepresented themainﬁndings of the review results in a ’Summary
of ﬁndings’ table, reporting the quality of evidence (according to
Atkins 2004), the magnitude of effect of the interventions exam-
ined, and the sumof available data on symptomatic recurrent VTE
at three months, symptomatic recurrent DVT at three months,
PE at three months, VTE-related mortality at three months, ma-
jor bleeding, all-cause mortality and asymptomatic VTE at three
months, . We used the GRADEpro software to assist in the prepa-
ration of the ’Summary of ﬁndings’ table (GRADEpro GDT).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
For this update, we identiﬁed one additional study that met the
inclusion criteria for this review (Leizorovicz 2011), bringing the
total number of included studies to 16 randomised controlled tri-
als, involving 3593 participants (Andersson 1982; Belcaro 1999;
Bentley 1980; Doyle 1987; Faivre 1987; Holm 1986; Hull 1986;
Kearon 2006; Krähenbühl 1979; Leizorovicz 2011; Lopaciuk
1990; Lopaciuk 1992; Peternel 2002; Pini 1990; Prandoni 2004;
Walker 1987). For detailed descriptions see Characteristics of
included studies and Appendix 3.
Eight studies compared subcutaneous UFH versus intravenous
UFH (Andersson 1982; Bentley 1980; Doyle 1987; Hull 1986;
Krähenbühl 1979; Lopaciuk 1990; Pini 1990; Walker 1987),
seven studies compared subcutaneousUFHversus LMWH(Faivre
1987; Holm 1986; Kearon 2006; Leizorovicz 2011; Lopaciuk
1992; Peternel 2002; Prandoni 2004), and one study compared
subcutaneous UFH to both intravenous UFH and subcutaneous
LMWH (Belcaro 1999).. For the long-term treatment, nine stud-
ies utilised warfarin, three used acenocoumarol, and one used
subcutaneous UFH. In three studies, the long-term management
was not clear. Thirteen trials monitored the subcutaneous heparin
dose through aPTTmeasurements and one through anti-factor Xa
(anti-Xa) measurements, while in two studies the subcutaneous
heparin dose was ﬁxed or based solely on weight.
Fourteen studies took place in an inpatient setting (Andersson
1982; Bentley 1980; Doyle 1987; Faivre 1987; Holm 1986;
Hull 1986; Krähenbühl 1979; Leizorovicz 2011; Lopaciuk 1990;
Lopaciuk 1992; Peternel 2002; Pini 1990; Prandoni 2004;Walker
1987), and two in both inpatient and outpatient settings (Belcaro
1999; Kearon 2006). All trials included participants with DVT.
Four trials allowed for participants with PE in their inclusion
criteria (Faivre 1987; Kearon 2006; Leizorovicz 2011; Prandoni
2004). Four trials excluded people with PE (Doyle 1987; Holm
1986; Peternel 2002; Walker 1987), and an additional two trials
excluded people with massive PE (Faivre 1987; Lopaciuk 1990).
The remaining trials did not clearly describe PE inclusion. We did
not identify any trials that included only participants with PE.
Studies recruited participants upon diagnosis of VTE and ran-
domised them to treatment groups. Eight of the included studies
administered an initial intravenous heparin bolus prior to initiat-
ing subcutaneous heparin treatment (Andersson 1982;Hull 1986;
Krähenbühl 1979; Leizorovicz 2011; Lopaciuk 1990; Lopaciuk
1992; Peternel 2002; Prandoni 2004). One study maintained the
infusion for 24 hours before the ﬁrst subcutaneous administra-
tion (Holm 1986). The duration of the intervention ranged from
a minimum of seven days to achievement of international nor-
malised ratio (INR) target level for oral anticoagulation in all in-
cluded trials apart from one, which administered subcutaneous
heparin for three months (Belcaro 1999). Diagnostic modalities
for DVT included venous occlusion plethysmography, thermog-
raphy, phlebography, venography, and colour-duplex sonography;
as well as lung scan or CT-angiography for PE. Follow-up length
was as long as the intervention duration in eight studies and
three months in seven studies (Belcaro 1999; Doyle 1987; Hull
1986; Kearon 2006; Lopaciuk 1990; Lopaciuk 1992; Prandoni
2004). One study reported death rate at 12 months (Doyle 1987).
One study was terminated early, as an interim safety analysis re-
vealed an excess mortality rate in the subcutaneous heparin group
(Leizorovicz 2011).
Excluded studies
After careful evaluation of the full publications, we excluded
nine additional studies from this update (Nakamura 2010;
NCT01956955;Quiros 2001;Riess 2014;Rodgers 1999;Romera
2009; Ucar 2015; Van Doormaal 2009; Van Doormaal 2010), for
a total number of 16 excluded studies. The main reasons for exclu-
sion were the method of administration of heparin and involve-
ment of thrombolysis or VTE prophylaxis. For further details see
Characteristics of excluded studies.
Risk of bias in included studies
For details on methodological quality of included studies, see
Figure 2 and Figure 3.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Five studies described the use of computer-generated random se-
quences (Hull 1986; Kearon 2006; Leizorovicz 2011; Pini 1990;
Prandoni 2004), one study described ’drawingof lots’ (Krähenbühl
1979), and another study described the use of a random number
table to allocate participants to treatment groups (Walker 1987).
We therefore deemed these seven studies to be at low risk of se-
lection bias. All other studies stated that they randomised partici-
pants but did not provide a clear description of random sequence
generation, so we considered them to be at unclear risk of selec-
tion bias (Andersson 1982; Belcaro 1999; Bentley 1980; Doyle
1987; Faivre 1987; Holm 1986; Lopaciuk 1990; Lopaciuk 1992;
Peternel 2002).
We judged eight studies to be at low risk of selection bias due to
allocation concealment (Bentley 1980; Doyle 1987; Kearon 2006;
Leizorovicz 2011; Lopaciuk 1990; Lopaciuk 1992; Prandoni
2004; Walker 1987). Five of these studies described the use of
’sealed envelopes’ to maintain allocation concealment (Bentley
1980;Doyle 1987; Lopaciuk 1990; Lopaciuk 1992;Walker 1987).
The Cochrane Handbook for Systematic Reviews of Interventions
states that allocation concealment should be achieved through se-
quentially numbered, opaque, sealed envelopes, opened only after
irreversible assignment to a participant. However, due to the age
of the studies included in this review, we decided that studies de-
scribing the use of envelopes to maintain allocation concealment
would be at lower risk of selection bias than those that did not
and that we would deem them to be at low risk. Three studies de-
scribed the use of central telephone randomisation (Kearon 2006;
Leizorovicz 2011; Prandoni 2004). Leizorovicz 2011 speciﬁcally
stated that “no allocation concealment mechanism was attempted
as the study was open”; however, we still considered the study to
be at low risk of selection bias, as this statement appeared to con-
tradict the description of “central telephone randomisation”. We
therefore assumed that the authors were referring to the blinding
of participants and personnel as “allocation concealment”. Fur-
thermore, authors also stated that “care was taken to ensure that
outcome assessors and data analysts were kept blinded to the allo-
cation”.
We judged Holm 1986 to be at high risk of selection bias due to
allocation concealment. Authors stated that participants’ alloca-
tions to treatment groups depended on the order of participant
admission: “the vials [of low molecular weight or unfractionated
heparin] had been randomised in advance and numbered consec-
utively, the number of patient admission determining the number
of vial used”. As personnel potentially had knowledge of the order
of the vials - allowing them to control the composition of the treat-
ment groups by manipulating the order of participant admission
- we deemed this study to be at high risk of selection bias.
No other studies provided descriptions of allocation concealment,
so we deemed them to be at unclear risk for allocation conceal-
ment (Andersson 1982; Belcaro 1999; Faivre 1987; Hull 1986;
Krähenbühl 1979; Peternel 2002; Pini 1990).
Blinding
Only one study adequately reported the blinding of participants
and personnel, so we considered it as being at low risk of perfor-
mance bias (Hull 1986). One study reported that it was “double-
blind” but did not provide any further information, so we assessed
it as being at unclear risk (Holm 1986). The remaining fourteen
studies were not blinded, so we considered them to be at high
risk of performance bias (Andersson 1982; Belcaro 1999; Bentley
1980; Doyle 1987; Faivre 1987; Kearon 2006; Krähenbühl 1979;
Leizorovicz 2011; Lopaciuk 1990; Lopaciuk 1992; Peternel 2002;
Pini 1990; Prandoni 2004; Walker 1987).
For measuring the risk of detection bias, we decided that due to
the subjective nature of certain criteria, we would rate studies as
being at high risk of detection bias if they did not adequately blind
for the following outcomes: recurrent VTE at three months; re-
current DVT at three months; PE - excluding PE found at au-
topsy; incidence of asymptomatic VTE at three months; quality
of life; and incidence of HIT. However, we thought that VTE-
related mortality at three months, all-cause mortality and major
and minor bleeding (if they followed the deﬁnition provided by
the International Society on Thrombosis and Haemostasis) were
objective enough to not require blinding.
In total, we judged eight studies to be at low risk of detection
bias (Belcaro 1999; Doyle 1987; Faivre 1987; Hull 1986; Kearon
2006; Leizorovicz 2011; Peternel 2002; Prandoni 2004). Two
studies were only included in the analysis of VTE-related mortal-
ity at three months and all-cause mortality, so we automatically
deemed them to be at low risk of detection bias (Faivre 1987;
Peternel 2002), while six studies adequately blinded for all six sub-
jective outcomes (Belcaro 1999; Doyle 1987; Hull 1986; Kearon
2006; Leizorovicz 2011; Prandoni 2004). The remaining eight
studies did not state whether personnel assessing suspected PE
were adequately blinded, so we deemed them to be at unclear risk
of detection bias (Andersson 1982; Bentley 1980; Holm 1986;
Krähenbühl 1979; Lopaciuk 1990; Lopaciuk 1992; Pini 1990;
Walker 1987).
Incomplete outcome data
Nine studies adequately accounted for all missing data, and we
judged them to be at low risk of attrition bias (Doyle 1987; Holm
1986;Hull 1986; Kearon2006; Leizorovicz 2011; Lopaciuk 1990;
Lopaciuk 1992; Prandoni 2004; Walker 1987). The remaining
seven studies did not adequately deal with missing data, so we
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deemed them to be at high risk of attrition bias (Andersson 1982;
Belcaro 1999; Bentley 1980; Faivre 1987; Krähenbühl 1979;
Peternel 2002; Pini 1990).
Selective reporting
Due to the age of the studies included in the review, there was
only one available protocol for an included study (Kearon 2006).
We therefore based our judgements of selective reporting solely on
the reporting of pre-speciﬁed outcomes in the Methods sections.
Fifteen papers reported on all pre-speciﬁed outcomes, and we
deemed them to be at low risk of reporting bias (Andersson 1982;
Belcaro 1999; Bentley 1980; Doyle 1987; Faivre 1987;Hull 1986;
Kearon 2006; Krähenbühl 1979; Leizorovicz 2011; Lopaciuk
1990; Lopaciuk 1992; Peternel 2002; Pini 1990; Prandoni 2004;
Walker 1987). We considered one study to be at high risk of re-
porting bias, as authors presented results for leg pain but did not
present the method of measuring pain in the Methods section
(Holm 1986).
Other potential sources of bias
We rated 15 studies as being at low risk of other bias (Andersson
1982; Bentley 1980; Doyle 1987; Faivre 1987; Holm 1986;
Hull 1986; Kearon 2006; Krähenbühl 1979; Leizorovicz 2011;
Lopaciuk 1990; Lopaciuk 1992; Peternel 2002; Pini 1990;
Prandoni 2004; Walker 1987). We considered the risk of other
bias to be unclear in one study, as different groups received treat-
ment in different locations, with groups 1 and 2 receiving different
treatments in hospital and group 3 receiving treatment at home
(Belcaro 1999).
Effects of interventions
See: Summary of ﬁndings for the main comparison
Subcutaneous unfractionated heparin compared to intravenous
unfractionated heparin for the initial treatment of venous
thromboembolism; Summary of ﬁndings 2 Subcutaneous
unfractionated heparin compared to lowmolecular weight heparin
for the initial treatment of venous thromboembolism
For a summary of outcomes see Summary of ﬁndings for the main
comparison; Summary of ﬁndings 2. For details of outcomes see
Data and analyses.
Subcutaneous UFH versus intravenous UFH
Symptomatic recurrent VTE at three months
Eight studies with a combined total of 965 participants measured
recurrent VTE at three months (Andersson 1982; Bentley 1980;
Doyle 1987; Hull 1986; Krähenbühl 1979; Lopaciuk 1990; Pini
1990; Walker 1987). The rate of recurrence was similar between
participants treated with subcutaneous (27 events/485 partici-
pants) versus IV UFH (17 events/480 participants), leading to an
odds ratio (OR) of 1.66 (95% CI 0.89 to 3.10; N = 965; 8 stud-
ies; I2 = 0%; low-quality evidence; Analysis 1.1). All eight studies
excluded participants with PE, so we could not perform subgroup
analysis based on VTE at randomisation.
Symptomatic recurrent DVT at three months
One study with 115 participants measured recurrentDVT at three
months (Hull 1986), ﬁnding a similar rate between participants
treated with subcutaneous (6 events/57 participants) versus IV
UFH (2 events/58 participants), leading to an OR of 3.29 (95%
CI 0.64 to 17.06; N = 115; 1 study; low-quality evidence; Analysis
1.2). This study included only DVT participants, so we could not
perform subgroup analysis based on VTE at randomisation.
PE at three months
Nine studies with a combined total of 1161 participants mea-
sured incidence of PE at three months (Andersson 1982; Belcaro
1999; Bentley 1980; Doyle 1987; Hull 1986; Krähenbühl 1979;
Lopaciuk 1990; Pini 1990; Walker 1987). Incidence was similar
between participants treated with subcutaneous (21 events/584
participants) versus IV UFH (15 events/577 participants), leading
to an OR of 1.44 (95% CI 0.73 to 2.84; N = 1161; 9 studies; I2 =
0%; low-quality evidence; Analysis 1.3). All nine studies excluded
participants with PE, so we could not perform subgroup analysis
based on VTE at randomisation.
VTE-related mortality at three months
Nine studies with a combined total of 1168 participants mea-
sured VTE-related mortality at three months (Andersson 1982;
Belcaro 1999; Bentley 1980; Doyle 1987; Hull 1986; Krähenbühl
1979; Lopaciuk 1990; Pini 1990; Walker 1987). However, only
three studies reported any cases of this outcome (Hull 1986;
Lopaciuk 1990; Pini 1990), which was similar for participants
treated with subcutaneous (2 events/588 participants) versus IV
UFH (2 events/580 participants), leading to an OR of 0.98 (95%
CI 0.20 to 4.88; N = 1168; 9 studies; I2 = 0%; low-quality evi-
dence; Analysis 1.4). All nine studies excluded participants with
PE, so we could not perform subgroup analysis based on VTE at
randomisation.
Major bleeding
Four studies with a combined total of 583 participants measured
incidence of major bleeding during the study period (Doyle 1987;
Hull 1986; Lopaciuk 1990; Pini 1990). The incidence of major
bleeding was similar between participants treated with subcuta-
neous (13 events/294 participants) versus IVUFH (14 events/289
participants), leading to an OR of 0.91 (95% CI 0.42 to 1.97;
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N = 583; 4 studies; I2 = 0%; low-quality evidence; Analysis 1.5).
All four studies excluded participants with PE, so we could not
perform subgroup analysis based on VTE at randomisation.
All-cause mortality
Eight studies with a combined total of 972 participants measured
all-cause mortality (Andersson 1982; Bentley 1980; Doyle 1987;
Hull 1986; Krähenbühl 1979; Lopaciuk 1990; Pini 1990; Walker
1987). This outcome was similar for participants treated with sub-
cutaneous (11 events/489 participants) versus IV UFH (6 events/
483 participants), leading to an ORof 1.74 (95%CI 0.67 to 4.51;
N = 972; 8 studies; I2 = 0%; low-quality evidence; Analysis 1.6).
All eight studies excluded participants with PE, so we could not
perform subgroup analysis based on VTE at randomisation.
Asymptomatic VTE at three months
No studies comparing subcutaneous UFHwith IV UFH reported
any episodes of asymptomatic VTE occurringwithin threemonths
of the commencement of treatment.
Treatment-related morbidity
Minor bleeding
Five studieswith a combined total of 779participantsmeasured in-
cidence of minor bleeding during the study period (Belcaro 1999;
Doyle 1987; Hull 1986; Lopaciuk 1990; Pini 1990). Incidence
was similar for participants treated with subcutaneous (18 events/
393 participants) versus IV UFH (26 events/386 participants),
leading to an OR of 0.63 (95% CI 0.33 to 1.20; N = 779; 5 stud-
ies; I2 = 0%; low-quality evidence; Analysis 1.7). All ﬁve studies
excluded participants with PE, so we could not perform subgroup
analysis based on VTE at randomisation.
Heparin-induced thrombocytopenia
None of the studies comparing subcutaneous UFH with IV UFH
reported episodes of HIT.
Length of hospital stay
The study by Belcaro 1999 measured days in hospital, but the
subcutaneous UFH group were treated at home, so we could not
make a comparison. The mean (± standard deviation) length of
hospital stay in the IV UFH group was 5.4 ± 1.4 days.
Quality of life
None of the included studies measured quality of life as an out-
come.
Subcutaneous UFH versus LMWH
Symptomatic recurrent VTE at three months
Five studies with a combined total of 2156 participants mea-
sured recurrent VTE at three months (Holm 1986; Kearon 2006;
Leizorovicz 2011; Lopaciuk 1992; Prandoni 2004). The rate of
recurrent VTE at three months was similar for participants treated
with subcutaneous UFH (34 events/1071 participants) versus
LMWH (34 events/1085 participants), leading to an OR of 1.01
(95% CI 0.63 to 1.63; N = 2156; 5 studies; I2 = 0%; low-quality
evidence; Analysis 2.1). We observed no differences between the
VTE at randomisation subgroups ’DVT with/without PE’ versus
’DVT without PE’ (P = 0.38).
Symptomatic recurrent DVT at three months
Three studieswith a combined total of 1566 participantsmeasured
recurrent DVT at three months (Kearon 2006; Lopaciuk 1992;
Prandoni 2004), ﬁnding similar rates for participants treated with
subcutaneous UFH (22 events/780 participants) versus LMWH
(16 events/786 participants), leading to an OR of 1.38 (95% CI
0.73 to 2.63; N = 1566; 3 studies; I2 = 0%; low-quality evidence;
Analysis 2.2). We observed no differences between the VTE at
randomisation subgroups ’DVT with/without PE’ versus ’DVT
without PE’ (P = 0.37).
PE at three months
Five studies with a combined total of 1819 participants mea-
sured incidence of PE at threemonths (Belcaro 1999; Holm 1986;
Kearon2006; Lopaciuk 1992; Prandoni 2004). Incidencewas sim-
ilar for participants treated with subcutaneous UFH (9 events/906
participants) versus LMWH (11 events/913 participants), leading
to an OR of 0.84 (95% CI 0.36 to 1.96; N = 1819; 5 studies; I2 =
0%; low-quality evidence) (Analysis 2.3). We observed no differ-
ences between the VTE at randomisation subgroups ’DVTwith/
without PE’ versus ’DVT without PE’ (P = 0.81).
VTE-related mortality at three months
Eight studies with a combined total of 2469 participants mea-
suredVTE-relatedmortality at threemonths (Belcaro 1999; Faivre
1987; Holm 1986; Kearon 2006; Leizorovicz 2011; Lopaciuk
1992; Peternel 2002; Prandoni 2004). The outcome was similar
for participants treated with subcutaneous UFH (4 events/1230
participants) versus LMWH (8 events/1239 participants), leading
to an OR of 0.53 (95% CI 0.17 to 1.67; N = 2469; 8 studies; I
2 = 0%; low-quality evidence; Analysis 2.4). There were no cases
of VTE-related mortality in the four studies incorporating partic-
ipants with DVT but without PE.
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Major bleeding
Five studies with a combined total of 2300 participants measured
incidence of major bleeding during the study period (Belcaro
1999; Kearon 2006; Leizorovicz 2011; Lopaciuk 1992; Prandoni
2004). The incidence of major bleeding was similar for partici-
pants treated with subcutaneous UFH (26 events/1147 partici-
pants) versus LMWH (36 events/1153 participants), leading to an
OR of 0.72 (95% CI 0.43 to 1.20; N = 2300; 5 studies; I2 = 0%;
low-quality evidence; Analysis 2.5). We observed no differences
between the VTE at randomisation subgroups DVT regardless of
PE status versus DVT without PE(P = 0.36).
All-cause mortality
Seven studies with a combined total of 2272 participants mea-
sured all-cause mortality (Faivre 1987; Holm 1986; Kearon 2006;
Leizorovicz 2011; Lopaciuk 1992; Peternel 2002; Prandoni 2004).
This outcome was similar for participants treated with subcu-
taneous UFH (49 events/1131 participants) versus LMWH (66
events/1141 participants), leading to an OR of 0.73 (95% CI
0.50 to 1.07; N = 2272; 7 studies; I2 = 0%; low-quality evidence;
Analysis 2.6). We observed no differences between the VTE at
randomisation subgroups ’DVT with/without PE’ versus ’DVT
without PE’ (P = 0.41).
Asymptomatic VTE at three months
There were no episodes of asymptomatic VTE occurring within
three months of the commencement of treatment reported by any
studies comparing subcutaneous UFH versus LMWH.
Treatment-related morbidity
Minor bleeding
Five studies with a combined total of 2300 participants measured
incidence of minor bleeding within the study period (Belcaro
1999; Kearon 2006; Leizorovicz 2011; Lopaciuk 1992; Prandoni
2004). The incidence of minor bleeding was similar for partic-
ipants treated with subcutaneous UFH (81 events/1147 partici-
pants) versus LMWH (83 events/1153 participants), leading to
an OR of 0.98 (95% CI 0.71 to 1.37; N = 2300; 5 studies; I2 =
0%;; Analysis 2.7). We observed no differences between the VTE
at randomisation subgroups ’DVTwith/without PE’ versus ’DVT
without PE’ (P = 0.93).
Heparin-induced thrombocytopenia
Three studieswith a combined total of 1954 participantsmeasured
the incidence of HIT (Kearon 2006; Leizorovicz 2011; Prandoni
2004). The outcome was similar for participants treated with sub-
cutaneous UFH (3 events/972 participants) versus LMWH (2
events/982 participants), leading to an OR of 1.52 (95% CI 0.25
to 9.14; N = 1954; 3 studies; I2 = 0%; Analysis 2.8). All three
studies included participants with PE, so we could not perform
subgroup analysis based on VTE at randomisation.
Length of hospital stay
Belcaro 1999 measured days in hospital, but the subcutaneous
UFH group received treatment at home, so we could not make
a comparison. The mean length of hospital stay in the LMWH
group was 5.1 ± 1.0 days.
Quality of life
None of the included studiesmeasured quality of life as an outcome
Subgroup analysis
Data were not available for subgroup analysis by ﬁrst or recurrent
VTE, severity of VTE, age of participants, renal function or un-
derlying pathology of VTE. Additionally, data were not available
for subgroup analysis by number of daily subcutaneous heparin
injections, type of dose adjustment, initial intravenous bolus hep-
arin given versus not given, concomitant oral anticoagulant use or
timing of oral anticoagulant initiation. We report results of sub-
group analyses by VTE at randomisation above.
Sensitivity analysis
We performed sensitivity analyses in order to explore the inﬂu-
ence of certain factors on effect size. We considered two studies
large compared with others (Kearon 2006; Prandoni 2004). Both
compared subcutaneous UFH versus LMWH. Exclusion of these
trials from the analysis of outcomes did not inﬂuence the results
(Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4; Analysis
3.5; Analysis 3.6; Analysis 3.7). We did not analyse the effect of
published versus unpublished trials, as no unpublished data were
available. Sensitivity of the results to the quality of trials was not
feasible, as we judged all but one trial to be at a high risk of bias.
Furthermore, we could not perform sensitivity analyses by diag-
nostic criteria, language of publication or source of funding due
to insufﬁcient data.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Subcutaneous unfractionated heparin compared to low molecular weight heparin for the initial treatment of venous thromboembolism
Patient or population: people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Setting: inpat ient and outpat ient
Intervention: subcutaneous unf ract ionated heparin
Comparison: low molecular weight heparin
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Risk with low molecular
weight heparin
Risk with subcutaneous un-
fractionated heparin
Symptomatic recurrent VTE
at 3 months
Study populat ion OR 1.01
(0.63 to 1.63)
2156
(5 RCTs)
⊕⊕©©
Lowa
31 per 1000 32 per 1000
(20 to 50)
Symptomatic recurrent DVT
at 3 months
Study populat ion OR 1.38
(0.73 to 2.63)
1566
(3 RCTs)
⊕⊕©©
Lowb
20 per 1000 28 per 1000
(15 to 52)
PE at 3 months Study populat ion OR 0.84
(0.36 to 1.96)
1819
(5 RCTs)
⊕⊕©©
Lowa
12 per 1000 10 per 1000
(4 to 23)
VTE-related mortality at 3
months
Study populat ion OR 0.53
(0.17 to 1.67)
2469
(8 RCTs)
⊕⊕©©
Lowc
6 per 1000 3 per 1000
(1 to 11)
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Major bleedingd (3 months) Study populat ion OR 0.72
(0.43 to 1.20)
2300
(5 RCTs)
⊕⊕©©
Lowa
31 per 1000 23 per 1000
(14 to 37)
All-cause mortality (7 days -
3 months)
Study populat ion OR 0.73
(0.50 to 1.07)
2272
(7 RCTs)
⊕⊕©©
Lowe
58 per 1000 43 per 1000
(30 to 62)
Asymptomatic VTE at 3
months
No study measured this outcome
* The basis for the assumed risk was the average risk in the low molecular weight heparin group (i.e. the number of part icipants with events divided by total number of
part icipants of the low molecular weight heparin group included in the meta-analysis). The risk in the subcutaneous unfractionated heparin group (and its 95% conf idence
interval) is based on the assumed risk in the low molecular weight heparin group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; DVT : deep vein thrombosis; PE: pulmonary embolism; RCT : randomised controlled trial; OR: odds rat io; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aWe downgraded the quality of the evidence to low due to high risk of select ion and report ing bias in one study (Holm 1986),
plus a high risk of performance bias in four studies (Kearon 2006; Leizorovicz 2011; Lopaciuk 1992; Prandoni 2004). We
also downgraded for imprecision, as ref lected by the wide conf idence intervals.
bWe downgraded the quality of the evidence to low due to a high risk of performance bias in three studies (Kearon 2006;
Lopaciuk 1992; Prandoni 2004). We also downgraded for imprecision, as ref lected by the wide conf idence intervals.
cWe downgraded the quality of the evidence to low due to a high risk of performance bias in seven studies (Belcaro 1999;
Faivre 1987; Kearon 2006; Leizorovicz 2011; Lopaciuk 1992; Peternel 2002; Prandoni 2004), a high risk of attrit ion bias in
three studies (Belcaro 1999; Faivre 1987; Peternel 2002), and a high risk of select ion and report ing bias in one study (Holm
1986). We also downgraded for imprecision, as ref lected by the wide conf idence intervals.
d Major bleeding as def ined by the Internat ional Society on Thrombosis and Haemostasis (ISTH) (Schulman 2005); fatal
bleeding; symptomatic bleeding in a crit ical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-
art icular or pericardial, or intramuscular with compartment syndrome; bleeding causing a fall in haemoglobin level of 20 g/
L (1.24 mmol/ L) or more, or leading to transfusion of two or more units of whole blood or red cells; any combinat ion of the
above.
1
9
S
u
b
c
u
ta
n
e
o
u
s
u
n
fra
c
tio
n
a
te
d
h
e
p
a
rin
fo
r
th
e
in
itia
l
tre
a
tm
e
n
t
o
f
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
eWe downgraded the quality of the evidence to low due to a high risk of performance bias in six studies (Faivre 1987; Kearon
2006; Leizorovicz 2011; Lopaciuk 1992; Peternel 2002; Prandoni 2004), a high risk of attrit ion bias in two studies (Faivre 1987;
Peternel 2002), and a high risk of select ion and report ing bias in one study (Holm 1986). We also downgraded for imprecision
ref lected by the wide conf idence intervals.
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D I S C U S S I O N
Summary of main results
Symptomatic recurrent VTE at three months
Meta-analyses showed no difference in the rate of symptomatic
recurrent VTE at three months between subcutaneous UFH ver-
sus IV UFH or LMWH. Our analyses showed little or no statis-
tical heterogeneity between the included studies. When compar-
ing subcutaneous UFH versus LMWH, the subgroup analysis by
VTE at randomisation showed no difference between participants
that had DVT without PE and those that had DVT with/without
PE. Furthermore, we observed no difference when excluding two
large studies from the analysis.
Symptomatic recurrent DVT at three months
Meta-analyses showed no difference in the rate of symptomatic re-
current DVT at three months between subcutaneous UFH versus
IV UFH or LMWH.
PE at three months
Meta-analyses showed no difference in the rate of PE between
subcutaneous UFH and IV UFH nor LMWH. When comparing
subcutaneous UFH versus LMWH, subgroup analysis by VTE
at randomisation showed no difference between participants that
had DVT without PE and those that had DVT with/without PE.
VTE-related mortality at three months
Meta-analyses showed no difference in the rate of VTE-related
mortality at three months between subcutaneous UFH versus IV
UFH or LMWH. There were no cases of VTE-relatedmortality in
the four studies incorporating participants that had DVT without
PE. Furthermore, we observed no difference when excluding two
large studies from the analysis.
Major bleeding
Meta-analyses showed no difference in the rate of major bleeding
between subcutaneous UFH versus IV UFH or LMWH. When
comparing subcutaneous UFH versus LMWH, subgroup analysis
by VTE at randomisation showed no difference between partici-
pants that had DVT without PE and those that had DVT with/
without PE. Furthermore, we observed no difference when ex-
cluding two large studies from the analysis.
All-cause mortality
Meta-analyses showed no difference in the rate of all-cause mor-
tality between subcutaneous UFH versus IV UFH or LMWH.
When comparing subcutaneous UFH versus LMWH, subgroup
analysis by VTE at randomisation showed no difference between
participants that had DVT without PE and those that had DVT
with/without PE.
Asymptomatic VTE at three months
None of the included studies reported any episodes of asymp-
tomatic VTE occurring within three months of the commence-
ment of treatment.
Treatment-related morbidity
Minor bleeding
Meta-analyses showed no difference in the incidence of minor
bleeding between subcutaneous UFH and IV UFH or LMWH.
When comparing subcutaneous UFH versus LMWH, subgroup
analysis by VTE at randomisation showed no difference between
participants that had DVT without PE and those that had DVT
with/without PE. Furthermore, we observed no difference when
excluding two large studies from the analysis.
Heparin-induced thrombocytopenia
None of the studies comparing subcutaneousUFHversus IVUFH
reported any episodes of HIT.Meta-analyses showed no difference
in the incidence of HIT between participants treated with sub-
cutaneous UFH versus LMWH. When comparing subcutaneous
UFH versus LMWH, subgroup analysis by VTE at randomisation
showed no difference between participants that hadDVT without
PE and those that had DVT with/without PE. Furthermore, we
observed no difference when excluding two large studies from the
analysis.
Length of hospital stay
One three-armed study, comparing subcutaneous UFH versus IV
UFH versus LMWH, measured length of hospital stay associated
with each treatment. However, the subcutaneous UFH group re-
ceived treatment at home, so we could not make a comparison.
The mean length of hospital stay was 5.4 ± 1.4 days in the IV
UFH and 5.1 ± 1.0 days in the LWMH groups, respectively.
Quality of life
None of the included studies measured quality of life as an out-
come.
21Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Overall completeness and applicability of
evidence
This review assessed whether subcutaneous UFH reduced the rate
of recurrent VTE, VTE-related mortality, major bleeding and all-
cause mortality in participants with VTE. Eight studies used IV
UFH as the comparator and seven studies used LMWH, while
one three-armed trial compared all three of those treatment possi-
bilities. We did not identify trials comparing subcutaneous UFH
with other anticoagulant drugs. All trials included participants
with deep vein thrombosis. Seven trials excluded people with a PE,
four trials included PE participants, and the remaining trials did
not clearly describe PE inclusion. With the exception of asymp-
tomatic VTE at three months and health-related quality of life,
the included studies measured and reported all of the addressed
outcomes. As all the trials had strict inclusion criteria, resulting
in an overall participant population with almost identical condi-
tions, statistical heterogeneity was logically low for all outcomes.
Furthermore, studies used similar concentrations for each partic-
ular drug.
We planned subgroup analyses by ﬁrst or recurrent VTE, sever-
ity, age, renal function, underlying pathology, number of daily
subcutaneous heparin injections, type of dose adjustment, initial
intravenous bolus heparin given versus not given, concomitant
oral anticoagulant use, and timing of oral anticoagulant initiation.
However, we could not perform these subgroup analyses because
of the lack of participant-level data.
Although many researchers consider DVT and PE to be manifes-
tations of the same disorder, we elected to present them in the form
of subgroups, as there is evidence of clinically signiﬁcant differ-
ences between them. Most recurrent events occur at the same site
as the original thrombosis (in other words, in a person presenting
with a PE, a recurrent event after treatment is much more likely to
be another PE). For comparisons and outcomes where subgroup
analyses were possible, we did not observe any differences between
studies recruiting participants that had DVT without PE and par-
ticipants that had DVT with/without PE.
The American College of Chest Physicians (ACCP) clinical prac-
tice guidelines for the treatment of VTE suggest UFH as the treat-
ment of choice for patients with severe renal failure (Kearon 2012).
This is a grade 2C recommendation, based on low-quality evidence
that LMWH is associated with increased bleeding in patients with
impaired renal function. Only one trial included in our review
studied participants with impaired renal function (Leizorovicz
2011), comparing subcutaneous UFH versus LMWH tinzaparin
in the treatment of acute DVT. The trial was terminated early due
to a difference in mortality that favoured the group treated with
UFH. However, rates of major bleeding and recurrent VTE were
similar between the two groups.
Quality of the evidence
The risk of bias was high in 15 out of the 16 included studies,
reﬂecting low methodological quality (Figure 2; Figure 3). This
was largely due to the lack of blinding in 14 studies, which led to a
high risk of performance bias. The risk of detection bias was lower:
8 of the 16 included studies reported that outcomes assessors were
blinded to the treatment and adjudicated by a central independent
committee. We judged seven studies to be at high risk of attrition
bias for failing to account for missing data, one study to be at
high risk of selection bias because of insufﬁcient reporting of the
methods used to conceal treatment allocation, and another study
to be at high risk of reporting bias because it reported a signiﬁcant
result on an outcome that was not pre-speciﬁed. We could not
investigate publication bias because we could not assess asymmetry
in a funnel plot with the limited number of studies included in
the meta-analysis.
For all outcomes in both comparisons, we downgraded the quality
of the evidence to low due to the high risk of bias within each
included study and also due to imprecision stemming from the
small number of outcome events, as reﬂected by the wide conﬁ-
dence intervals.
Potential biases in the review process
The search was as comprehensive as possible, and we are conﬁ-
dent that we have included all relevant studies. However, the pos-
sibility remains that we missed some relevant trials, particularly
in the grey literature (for example conference proceedings). Two
review authors independently performed study selection and data
extraction in order to minimise bias in the review process. We
performed data collection according to the process suggested by
Cochrane. We also followed Cochrane processes as described by
Higgins 2011 for assessing the risk of bias.
Agreements and disagreements with other
studies or reviews
A meta-analysis comparing subcutaneous heparin with intra-
venous heparin published in 1992 concluded that the subcuta-
neous mode of administration was more efﬁcacious and less toxic
than the intravenous mode of administration (Hommes 1992).
Another more recent review of the literature comparing subcuta-
neous UFH versus subcutaneous LMWH concluded that subcu-
taneous UFH was an attractive alternative to LWMH for VTE,
being “cheap, effective and safe” (Munro 2008).
Since the introduction of LMWH, there has been a shift away from
the older and less easy-to-use UFH. Several other meta-analyses
of the medical literature have been published over the years, sug-
gesting enhanced efﬁcacy and safety proﬁle for LMWH (Erkens
2010; Gould 1999).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Low-quality evidence suggests there is no difference in effective-
ness between subcutaneous UFH, IV UFH and LMWH for pre-
venting recurrent VTE at three months, VTE-related mortality,
major bleeding and all-cause mortality. Therefore, for people with
difﬁcult venous access or people who could be treated at home,
subcutaneous UFH appears to be an acceptable alternative to IV
UFH. Futhermore, in patients with severe renal impairment, sub-
cutaneous UFH can be used instead of LMWH.
Implications for research
Further research is required to consolidate non-monitored sub-
cutaneous administration of UFH in the setting of VTE. Future
research should target speciﬁc patient groups, e.g. patients with
chronic kidney disease and elderly patients, and speciﬁcVTE states
(e.g. DVT versus PE), and researchers should analyse data sep-
arately for their response to the proposed intervention. Finally,
studies should evaluate cost-effectiveness, comparing continuous
infusions of UFH versus subcutaneous administration of LMWH.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersson 1982
Methods Study design: open randomised controlled trial
Duration of intervention: at least 5 days to INR target
Duration of follow-up: acute phase only
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Sweden
Number of study centres: 3
Setting: hospital
Number: 141 (SC UFH group 72; IV UFH group 69)
Age mean (range): SC UFH group 64 years (23 to 88); IV UFH group 64 years (20 to
88)
Sex (M/F): SC UFH group 47/25; IV UFH group 41/28
Inclusion criteria: clinical signs of acute DVT
Exclusion criteria: not stated
Diagnostic criteria: phlebography, venous occlusion plethysmography, thermography
Interventions Intervention (route, total dose/day, frequency): IV UFH bolus dose (sodium heparin)
(5000 IU/mL) followed by SC UFH (25000 IU/mL) twice daily aPTT adjusted +
warfarin
Control (route, total dose/day, frequency): IV UFH bolus dose (sodium heparin)
(5000 IU/mL) followed by continuous IV UFH aPTT adjusted + warfarin
Treatment before study: NA
Titration period: NA
Outcomes Primary outcome: therapeutic efﬁcacy with repeat imaging
Secondary outcomes: bleeding, pulmonary emboli, aPTT, heparin dose
Notes Stated aim of the study: assess therapeutic effect and number of complications in the
two groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
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Andersson 1982 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods
of administration meant adequate blinding
was most likely not achieved
“Intravenous infusions were administered
by mobile infusion pumps”
“Subcutaneous injections were given into
the anterior abdominal wall using a 23
gauge needle”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
High risk 40 participants (out of 141) withdrawn
from the study
“due to inabilities to achieve these inves-
tigations during weekends and holidays,
technical reasons or because some patients
refused further investigations”
19 participants withdrawn from the sub-
cutaneous group and 21 participants with-
drawn from the intravenous group. How-
ever, the number of participants withdrawn
for each reason is not presented
No deaths were reported as occurring dur-
ing the course of the study
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other biases
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Belcaro 1999
Methods Study design: open randomised aPTT-controlled trial
Duration of intervention: 3 months for SC heparin; until INR target in LMWH and
IV heparin
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Italy (Chieti and Pescara), UK
Number of study centres: 3
Setting: SC UFH - outpatient; LMWH - out/inpatient; IV UFH - inpatient
Number: 325 randomised, 294 completed the study (SCUFH 99; LMWH98; IVUFH
97)
Age (mean ± SD): SC UFH 54 ± 9 years; LMWH 54 ± 11 years; IV UFH 53 ± 10 years
Sex (M/F): SC UFH 52/47; LMWH 54/44; IV UFH 57/40
Inclusion criteria: acute proximal DVT diagnosed by colour duplex ultrasonography
Exclusion criteria: 2 or more previous episodes of DVT or PE, current active bleeding,
active ulcers, bleeding or coagulation disorder, concurrent PE, treatment for DVT with
standard heparin > 48 h, home treatment not possible, neoplasia requiring surgery or
chemotherapy in three months, likelihood of low compliance, pregnancy, platelets <
100,000 × 109/L
Diagnostic criteria: colour duplex
Interventions Intervention (route, total dose/day, frequency): SC heparin (12,500 IU twice daily),
ﬁxed dose (no oral anticoagulation) administered exclusively at home
Control (route, total dose/day, frequency): group 1: LMWH (100 Axa IU/kg twice
daily) administered primarily at home + warfarin; group 2: IV bolus (5000 IU) followed
by continuous IV UFH aPTT adjusted + warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: symptomatic or asymptomatic recurrent DVT or DVT extension at 3
months, bleeding during the administration of the study drug, PE, length of stay in
hospital, number of participants treated directly at home without admission
Notes Stated aim of the study: to compare intravenous standard heparin (in hospital) with
oral anticoagulant treatment to LMWH and oral anticoagulant treatment administrated
primarily at home, to SC heparin administered at home
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
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Belcaro 1999 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of open study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
RecurrentVTE at 3months: data not used -
results for symptomatic, asymptomatic and
extended VTE not presented separately
Recurrent DVT at 3 months: data not used
- see recurrent VTE at 3 months
PE - excluding PE found at autopsy: data
used - “All reported outcome events were
reviewed by a central panel including all
monitors and, by form evaluation, by ﬁve
external reviewers unaware of the treat-
ments assigned and the patient’s identity”
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: data not used - see recurrent
VTE at 3 months
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data not used - unclear
how many deaths occurred in each group
Incomplete outcome data (attrition bias)
All outcomes
High risk 31 (out of 325) participants were with-
drawn from the study
Although the paper states that six partici-
pants died during the course of the study -
all other withdrawals are unaccounted for
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Unclear risk Different groups were treated in different
locations with groups 1 and 2 receiving dif-
ferent treatments in hospital and group 3
receiving treatment at home
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Bentley 1980
Methods Study design: open randomised controlled trial
Duration of intervention: 7 days to INR target
Duration of follow-up: 7 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: UK
Number of study centres: 1
Setting: inpatient
Age (mean ± SD): SC UFH group 60.49 ± 14.32 years; IV UFH group 58.18 ± 12.66
years
Sex (M/F): not speciﬁed but describes “well matched for age, sex ...”
Inclusion criteria: acute calf DVT diagnosed by venography
Exclusion criteria: contra-indication to heparin, thrombus extension < 5 cm
Diagnostic criteria: venography
Interventions Intervention (route, total dose/day, frequency): SC UFH (calcium heparin), initial
dose 40,000 IU/day followed by aPTT-adjusted dose twice daily + warfarin
Control (route, total dose/day, frequency): IV UFH (sodium heparin), initial dose 40,
000 IU/day followed by aPTT-adjusted continuous dose + warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: cutaneous haematoma, macroscopic haematuria, major bleeding, DVT ex-
tension, new or extended PE, aPTT, heparin level
Notes Stated aim of the study: to compare the safety and efﬁcacy of IV and SC heparin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Low risk “Patients were randomised using sealed en-
velopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods of heparin administra-
tion - intravenous compared to subcuta-
neous - probably prevented adequate blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
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Bentley 1980 (Continued)
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Description of blinding outcome assessors
for PE
Incomplete outcome data (attrition bias)
All outcomes
High risk The study states 3 participants (out of 100)
were withdrawn from the study - but from
which groups is unclear
Later in the paper it states that the heparin
treatment of 6 participants was halted (2 in
SC group and 4 in IV group)
However, all participants are included in
the ﬁnal analysis of venographic results
without further explanation
No deaths were reported as occurring dur-
ing the course of the study
Selective reporting (reporting bias) Low risk Study states estimations of platelet count;
haemoglobin and hematocrit were made at
the beginning, middle and end of the trial
period - however - results are only presented
for participants with minor bleeds. Never-
theless these were not outcomes of our re-
view and therefore the study was judged to
be at low risk of reporting bias
Other bias Low risk No evidence of other biases
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Doyle 1987
Methods Study design: open randomised controlled trial
Duration of intervention: 10 days
Duration of follow-up: 12 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Canada
Number of study centres: 1
Setting: inpatients
Number: 103 SC UFH 51; IV UFH 52
Age mean (range): SC UFH 66.6 years (31 to 96); IV UFH 64.6 (25 to 94) years
Sex (M/F): SC UFH 23/28; IV UFH 32/20
Inclusion criteria: acute proximal or calf DVT diagnosed by venography
Exclusion criteria: clinically suspected PE, active peptic ulceration, bleeding disorder,
no informed consent
Diagnostic criteria: venography
Interventions Intervention (route, total dose/day, frequency): SC UFH (calcium heparin), initial
dose 15,000 IU, then twice daily, aPTT adjusted + warfarin
Control (route, total dose/day, frequency): IV UFH (calcium heparin), initial dose 5,
000 IU, then continuous, aPTT adjusted + warfarin
Treatment before study: NA
Outcomes Primary outcome: PE
Secondary outcomes: other lung scan abnormalities, bleeding, leg symptoms, death
Notes Stated aim of the study: to determine the efﬁcacy and safety of adjusted SC calcium
heparin compared with continuous IV calcium heparin as the initial treatment for acute
DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Low risk use of “sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of “open” trial design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: data used -
the scintigrams were interpreted in random
order by 2 experienced experimental ob-
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Doyle 1987 (Continued)
servers who were blinded to the method of
treatment
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - see recurrent VTE at 3 months
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7 participants (out of 103) were withdrawn
from the study - 4 in SC group; 3 in the IV
group
Reasons for withdrawal were clearly pre-
sented:
“2 had major bleeding; 1 refused the scan;
1 required surgery and 3 could not have the
scans for technical reasons”
During follow-up 10 participants died -
none from PE
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
Faivre 1987
Methods Study design: randomised controlled trial
Duration of intervention: 10 days
Duration of follow-up: 10 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: French
Participants Who participated: people with acute DVT and PE
Country: France
Number of study centres: 1
Setting: inpatient
Number: 68 SC UFH 35; SC LMWH 33 (number evaluated: 59 SC UFH 29; SC
LMWH 30)
Age (mean ± SD) : SC UFH 63.6 ± 16.2 years; SC LMWH 65.6 ± 14.8 years
Sex (M/F): 39/29
Inclusion criteria: acute DVT or PE diagnosed with phlebography or perfusion-venti-
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Faivre 1987 (Continued)
lation scan
Exclusion criteria: over 2 weeks of symptoms, massive PE
Diagnostic criteria: phlebography and lung scan
Interventions Intervention (route, total dose/day, frequency): SC UFH (calcium heparin) 500 IU/
kg/day in form of twice daily injections, aPTT adjusted
Control (route, total dose/day, frequency): SC LMWH 750 anti-Xa/kg/day in form
of twice daily injections
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, bleeding
Notes Stated aim of the study: to assess the efﬁcacy and safety of CY222 for the treatment of
DVT compared with SC heparin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Nodescriptionof blindingprovided and al-
though both treatments were administered
subcutaneously, the authors state that in the
CY222 group participants received a ﬁxed
dose of (750 U anti-Xa IC/kg/24 h) whist
in the unfractionated heparin group dosage
was adjusted to maintain partial thrombo-
plastin time, making it unlikely participant
and personnel were adequately blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: NA
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: NA
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
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Minor bleeding: NA
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 participants (out of 68) were withdrawn
from the study
In theCY22 group 3 participants withdrew
(cardiac insufﬁciency, migration of Green-
ﬁeld ﬁlter)
In the SC group 6 participants withdrew
(3 retroperitoneal haematoma; 3 recurrent
PE)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
Holm 1986
Methods Study design: double-blind randomised controlled trial
Duration of intervention: 7 days
Duration of follow-up: 7 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Norway
Number of study centres: 1
Setting: inpatients
Number: 56 (SC UFH 27; SC LMWH 29)
Age (mean ± SD): SC UFH 60 ± 15.8 years; SC LMWH 61 ± 15.3 years
Sex (M/F): 33/23 (SC UFH 17/10; SC LMWH 16/13)
Inclusion criteria: acute DVT below the groin diagnosed by phlebography, with symp-
toms for fewer than 14 days
Exclusion criteria: PE, pregnancy, history of cerebral haemorrhage, surgery in previous 6
days, diastolic BP > 115 mmHg, retinal haemorrhage, impaired renal function, impaired
PT
Diagnostic criteria: phlebography
Interventions Intervention (route, total dose/day, frequency): IV continuous infusion UFH for 24
hours, followed by SC UFH 10,000-15,000 IU twice daily, anti-Xa adjusted + warfarin
Control (route, total dose/day, frequency): IV continuous infusion UFH for 24 hours,
followed by SC LMWH 5000-7500 IU twice daily, anti-Xa adjusted + warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, new PE, bleeding, leg pain, death, haemoglobin, platelets
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Notes Stated aim of the study: to compare subcutaneous heparin and LMWH for the treat-
ment of DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) High risk “the vials [of low molecular weight or un-
fractionated heparin] had been randomised
in advance and numbered consecutively,
the number of patient admission determin-
ing the number of vial used”
It is possible personnel had access to the
order of the vials
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Paper states only “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding of out-
come assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants (out of 56) were withdrawn
from the trial - 2 from the LMWH group;
1 from UFH group
Reasons for withdrawals are clearly pre-
sented:
Reversal of DVT diagnosis; incorrect in-
jection of ordinary heparin and suspected
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cerebral haemorrhage
No deaths were reported as occurring dur-
ing the course of the study
Selective reporting (reporting bias) High risk Study presents results for leg pain “leg
pain disappeared somewhat quicker in pa-
tients receiving LH”; however, pain mea-
sures were not presented as an outcome in
the Methods section
In addition, the paper states that “there was
no drop in platelet count or haemoglobin
concentration”; however, how these param-
eters were measured is also unreported in
the Methods section
Other bias Low risk No signiﬁcant evidence of other biases;
however, one patient was included twice
(once in each group) and one patient trans-
ferred to the UFH group and so was not in-
cluded in the ﬁnal analysis This could po-
tentially be considered an as-treated anal-
ysis, and as such it may have potentially
introduced selection bias; however, as only
one patientwas affected the potential risk of
bias was considered small and was deemed
unlikely to have signiﬁcantly affected the
results of the study
Hull 1986
Methods Study design: double-blind randomised controlled trial
Duration of intervention: 10 days
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Canada
Number of study centres: 1
Setting: inpatients
Number: 115
Age (< 60 years / > 60 years): SC UFH 10/4; 7 IV UFH 11/47
Sex (M/F): SC UFH 27/30; IV UFH 28/30
Inclusion criteria: acute proximal (± calf ) DVT diagnosed by venography
Exclusion criteria: active bleeding, contraindication to heparin, already on heparin, no
outpatient follow-up available
Diagnostic criteria: venography
38Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hull 1986 (Continued)
Interventions Intervention (route, total dose/day, frequency): IV UFH 5000 IU bolus followed by
SC UFH 15000 twice daily, aPTT adjusted + warfarin
Control (route, total dose/day, frequency): IV UFH 5000 IU bolus followed by con-
tinuous IV UFH aPTT adjusted + warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: recurrent DVT, PE, bleeding, aPTT, death
Notes Stated aim of the study: to compare continuous IV heparin to intermittent SC heparin
for the initial treatment of proximal DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer generated prescribed ran-
domised arrangement was used to assign
patients”
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “those to receive continuous IV heparin
were ... started on a continuous IV infusion
… and placebo SC injections”
“those to receive SC heparin were given SC
heparin injections … and IV placebo infu-
sions”
“to prevent un-blinding … masked pre-la-
belled syringes and IV packs were used”
“to prevent un-blinding on the basis of
knowledge of heparin clearance … all dose
adjustments and anticoagulant monitoring
…were [done at a] daily mid interval mea-
surement”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: data used -
“[d]iagnostic tests were interpreted inde-
pendently and without knowledge of the
results of the other tests or the patient’s clin-
ical state or the treatment group to which
the patient had been assigned”
Recurrent DVT at 3 months: data used -
see recurrent VTE at 3 months
PE - excluding PE found at autopsy: data
used - See recurrent VTE at 3 months
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Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0 participants (out of 115) were withdrawn
from the study
“[A]ll patients were followed during pri-
mary therapy and for three months during
long term therapy and none were lost to
follow up”
6 participants died in the subcutaneous
group, 2 fromVTE-related causes; 3 partic-
ipants died in the intravenous group, none
from VTE-related causes
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other biases
Kearon 2006
Methods Study design: open-label, adjudicator-blinded randomised controlled trial
Duration of intervention: 5 days to INR target
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT or PE
Country: Canada and New Zealand
Number of study centres: 6
Setting: inpatients and outpatients
Number: 708 (SC UFH 355; SC LMWH 353)
Age (mean ± SD): SC UFH 60 ± 17 years; SC LMWH 60 ± 16 years
Sex (M/F): SC UFH 182/173; SC LMWH 206/147
Inclusion criteria: 18 years or older with newly diagnosed DVT of the legs or PE
diagnosed by compression ultrasonography or by venography, and by a high probability
ventilation-perfusion lung scan, by non diagnostic ﬁndings on lung scan accompanied
by diagnostic ﬁndings for DVT, or by computed tomographic angiography
Exclusion criteria: contraindication to subcutaneous therapy such as shock or major
surgery in the past 48 hours, active bleeding, a life expectancy of less than 3 months, pre-
vious acute treatment for venous thromboembolism for more than 48 hours, receiving
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long-term anticoagulant therapy, contraindication to heparin or to radiographic con-
trast, creatinine level of greater than 200 µmol/L (2.3 mg/dL), pregnant, enrolled in a
competing study, unable to have follow-up assessments because of geographic inaccessi-
bility
Diagnostic criteria: compression ultrasonography or venography, and high probability
ventilation-perfusion lung scan, non-diagnostic ﬁndings on lung scan accompanied by
diagnostic ﬁndings for deep vein thrombosis, or computed tomographic angiography
Type of VTE: 571 DVT/174 PE
Interventions Intervention (route, total dose/day, frequency): unmonitored SC UFH, initial 333
IU/kg followed by 250 IU/kg twice daily + warfarin
Control (route, total dose/day, frequency): SC LMWH 100 IU/kg twice daily + war-
farin
Treatment before study: NA
Outcomes Primary outcomes: the primary analysis for efﬁcacy was the absolute difference in the
proportion of eligible participants who had recurrent venous thromboembolism at 3
months. The primary analysis for safety was the absolute difference in the proportion
of participants who received at least 1 dose of study drug who had an episode of major
bleeding within 10 days of randomisation
Secondary outcomes: recurrent VTE at 10 days, major or minor bleeding, death, aPTT
Notes Stated aim of the study: to determine if ﬁxed-dose, weight-adjusted, subcutaneous un-
fractionated heparin is as effective and safe as lowmolecular-weight heparin for treatment
of venous thromboembolism
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was computer generated
with block sizes of 2 or 4”
Allocation concealment (selection bias) Low risk “[C]linical centres telephone an automated
centralised system”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of “open-label” study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: data used -
all outcome events and deaths were clas-
siﬁed by a central adjudication committee
whosemembers were unaware of treatment
assignment
Recurrent DVT at 3 months: data used -
see recurrent VTE at 3 months
PE - excluding PE found at autopsy: data
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used - see recurrent VTE at 3 months
Incidence of heparin-induced thrombocy-
topenia: data used - see recurrent VTE at 3
months
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11 participants (out of 708) were with-
drawn from the study - 10 in the UFH
group; 1 in the LMWH group
Reasons for withdrawals were clearly re-
ported and the asymmetry in the with-
drawals did not appear to be caused by the
different treatment methods:
UFH - 4 participants were receiving long-
term anticoagulant therapy; 3 diagnosis of
VTE were reversed; 1 randomisation error;
1 withdrawal of consent and 1 withdrawal
by physician
LMWH - 1 withdrawal of consent
During follow-up there were 18 deaths in
the UFH group (1 from bleeding) and 22
deaths in the LMWH group (3 from PE
and 1 from bleeding)
Selective reporting (reporting bias) Low risk Protocol available - no evidence of selective
reporting
Other bias Low risk No signiﬁcant evidence of other biases - 5
participants who did not receive the study
drug were not included in the ﬁnal analy-
sis of either safety or efﬁcacy - something
which could be considered an ’as-treated’
analysis that potentially introduced selec-
tion bias; however, the number of partici-
pants affected was considered too small to
have had a signiﬁcant impact on the results
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Methods Study design: randomised controlled trial
Duration of intervention: 7 days
Duration of follow-up: 6 weeks
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: French
Participants Who participated: people with acute DVT of the lower limb
Country: Switzerland
Number of study centres: 1
Setting: inpatients
Number: 48 (SC UFH 23; IV UFH 25)
Age: not stated
Sex (M/F): SC UFH 18/5; IV UFH 13/12)
Inclusion criteria: DVT of lower limbs diagnosed by phlebography or colour duplex
US, with symptoms < 1 week
Exclusion criteria: none stated
Diagnostic criteria: phlebography or colour duplex ultrasound
Interventions Intervention (route, total dose/day, frequency): IV bolusUFH (sodiumheparin) 5000
IU, followed by SC UFH 15,000U/day twice daily (aPTT adjusted)
Control (route, total dose/day, frequency): IV bolus UFH (sodium heparin) 5000 IU
followed by IV continuous UFH (aPTT adjusted)
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Primary Outcomes: symptoms duration, DVT extension, PE, aPTT
Notes Stated aim of the study: to compare subcutaneous heparin and intravenous heparin for
the treatment of deep vein thrombosis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Drawing of lots”
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods of heparin administra-
tion - intravenous compared to subcuta-
neous - probably prevented adequate blind-
ing
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 24 participants (out of 48) received
a second phlebograph: reasons for this loss
are not clearly presented in the article
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other biases
Leizorovicz 2011
Methods Study design: international, multicentre, centrally randomised, open, parallel-group
study with blinded adjudication
Duration of intervention: 90 ± 5 days
Duration of follow-up: NA
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people aged ≥ 75 years with creatinine clearance (CrCl) ≤ 60 mL/
min or people aged ≥ 70 years with a CrCl of ≤ 30 mL/min (calculated using the
Cockcroft-Gault formula) and with an acute, objectively conﬁrmed (by compression
ultrasonography or venography) lower limb DVT which required treatment
Countries: Belgium; France; Germany; Spain; Serbia; Croatia; Romania and Poland
Number of study centres: 8
Setting: inpatients at the time of randomisation; however, participants could be followed
on a daily basis in or out of hospital after this point
Number: 539
Age (< 60 years/ > 60 years): SC UFH 0/270; tinzaparin 0/269
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Sex (M/F): SC UFH 102/168; tinzaparin 92/177
Inclusion criteria: objectively conﬁrmed symptomatic proximal or distal DVT (or ob-
jectively conﬁrmed asymptomatic DVT if proximal and associated with a PE) and pro-
vision of written informed consent
Exclusion criteria: received treatment doses of heparins or thrombolytic agents within
the previous 4 weeks (excluding the last 36 h) prior to randomisation; received oral
anticoagulation within the preceding week; planned use of high doses of acetylsalicylic
acid (ASA) (> 300 mg/day) or a non-steroidal anti-inﬂammatory drug (NSAID); re-
quirement for thrombolytic therapy; end stage renal disease requiring dialysis; hepatic
insufﬁciency (INR≥ 1.5); bacterial endocarditis; planned epidural or spinal anaesthesia;
planned surgery or recent surgery (within 2 weeks); thrombocytopenia (< 100 x 109/L)
; severe uncontrolled hypertension, overt bleeding and recent stroke
Diagnostic criteria: compression ultrasonography or venography
Interventions Intervention (route, total dose/day, frequency): tinzaparin (SC, 175 IU/kg, once daily)
Control (route, total dose/day, frequency): UFH (IV, 50 IU/kg bolus followed by
SC, 400-600 IU/kg, twice daily which was then adjusted by APTT according to local
practice)
Treatment before study: NA
Outcomes Primary outcomes: clinically relevant bleedings (CRBs) by day 90 ± 5
Secondary outcomes: occurrence of symptomatic recurrent VTE prior to day 90 ± 5
and major and minor bleedings prior to day 90 ± 5
Tertiary outcomes: CRBs during the SC treatment phase, death from any cause prior
to day 90 ± 5 and heparin-induced thrombocytopenia
Notes Stated aim of the study: to compare the safety proﬁle of full weight-based unadjusted-
dose tinzaparin (Innohep, LEO Pharma, Ballerup, Denmark) vs activated partial throm-
boplastin time (APTT)-adjusted UFH as initial treatment of elderly participants with
impaired renal function and acute DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Treatment assignment was pre-planned
according to a computer generated ran-
domisation sequence”
Allocation concealment (selection bias) Low risk “Central telephone randomisation”
However, the paper also states:
“No allocation concealment mechanism
was attempted as the study was open. But
care was taken to ensure that outcome as-
sessors and data analysts were kept blinded
to the allocation”
This statement appears to be in contradic-
tion with the description of central tele-
phone randomisation and so it was as-
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sumed that in this context ’allocation con-
cealment’ referred to the blinding of par-
ticipants and personnel, as an open study
design does not preclude adequate alloca-
tion concealment - this assumptionwas also
more consistent with the reference to the
blinding of outcome assessors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of an “open” study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: data used -
care was taken to ensure that outcome as-
sessors and data analysts were kept blinded
to the allocation
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - see recurrent VTE at 3 months
Incidence of heparin-induced thrombocy-
topenia: data used - see recurrent VTE at 3
months
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5 participants (out of 539) were withdrawn
from the study for reasons that were clearly
presented:
2 from the tinzaparin group as “no treat-
ment [was] taken”
3 from the unfractionated heparin group 2
because of a withdrawal of consent and 1
because “no treatment [was] taken”
During the course of the study 48 partic-
ipants died: 31 participants from the tin-
zaparin group and 17 from the unfraction-
ated heparin group
The large imbalance in mortality between
the treatment groups has been addressed by
the authors and appears to have been caused
by an increased prevalence of speciﬁc risk
factors in the tinzaparin group including
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presence of infectious disease; ongoing ma-
lignancy; cardiac insufﬁciency; stratum of
renal impairment and leg paralysis, which
all correlated signiﬁcantly with mortality
Only 4 deaths could be directly attributed
to the heparin treatment
3 in the tinzaparin group - 2 from bleeding
and 1 from pulmonary embolism
1 in the unfractionated heparin group also
from pulmonary embolism
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No signiﬁcant evidence of other biases -
3 participants transferred from the unfrac-
tionated heparin to the tinzaparin group
and were included in the tinzaparin group
for the analysis of adverse effects - some-
thing which constitutes an ’as treated’ anal-
ysis and as such potentially introduced se-
lection bias; however, the number of par-
ticipants affected was considered too small
to signiﬁcantly affect the results
Lopaciuk 1990
Methods Study design: open randomised controlled trial
Duration of intervention: 7 days
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: Polish
Participants Who participated: people with acute proximal or calf DVT (with or without PE)
Country: Poland
Number of study centres: 5
Setting: inpatients
Number: 94 (SC UFH 48; IV UFH 46)
Age (mean ± SD): SC UFH 53.6 ± 13.1 years; IV UFH 50.5 ± 16.9 years
Sex (M/F): SC UFH 23/25; IV UFH 24/22
Inclusion criteria: calf or proximal DVT diagnosed by phlebography, age 20 to 79 years
Exclusion criteria: PE necessitating thrombolysis, gastric or duodenal ulcer
Diagnostic criteria: phlebography
Type of VTE: DVT
Interventions Intervention (route, total dose/day, frequency): bolus IVUFH (sodiumheparin) 5000
IU, followed by SC UFH 500 IU/kg/day twice daily, aPTT adjusted + sintron (after 7
days)
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Control (route, total dose/day, frequency): bolus IV UFH (sodium heparin) 5000 IU,
followed by continuous IV UFH aPTT adjusted + sintron (after 7 days)
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, aPTT, platelets, PE, bleeding, death
Notes Stated aim of the study: to compare efﬁcacy and safety of SC heparin versus IV heparin
for DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Low risk Use of “sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods of heparin administra-
tion - intravenous compared to subcuta-
neous - probably prevented adequate blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants (out of 94) were withdrawn
from the study
Reasons for withdrawals are clearly pre-
sented:
Intravenous group - 1 patient died follow-
ing a pulmonary embolism
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Subcutaneous group - 1 patient was with-
drawn because of bleeding
Inclusion of these participants into calcula-
tions does not change the results and they
participants are correctly included in the
analysis of bleeding and thrombotic com-
plications
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
Other bias Low risk No evidence of other biases
Lopaciuk 1992
Methods Study design: open, stratiﬁed randomised controlled trial with blind evaluation of phle-
bographic results
Duration of intervention: 10 days
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute proximal or calf DVT
Country: Poland
Number of study centres: 6
Setting: inpatients
Number: 149 (SC UFH 75 (3 excluded from analysis); SC LMWH 74)
Age (mean ± SD): SC UFH 47.8 ±15.4 years; SC LMWH 49.1 ± 15.4 years
Sex (M/F): SC UFH 42/30; SC LMWH 39/35
Inclusion criteria: calf or proximal DVT diagnosed by phlebography, symptoms shorter
than 10 days
Exclusion criteria: clinically suspected PE, phlegmasia caerulea dolens, treatment with
anticoagulation prior to enrolment, VTE in previous 2 years, surgery or trauma in recent
3 days, contraindication to heparin, pregnancy, ATIII deﬁciency
Diagnostic criteria: phlebography (blind evaluation of phlebographic results)
Interventions Intervention (route, total dose/day, frequency): bolus IV UFH 5000 IU, followed by
SC UFH 250 IU/kg twice daily, aPTT adjusted + sintron
Control (route, total dose/day, frequency): SC LMWH 225 IU/kg twice daily, ﬁxed
dose + sintron
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, recurrent DVT, PE, bleeding, death
Notes Stated aim of the study: to determine the efﬁcacy and safety of subcutaneous LMWH
compared with SC UFH as the initial treatment of DVT of the lower limbs
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Low risk Use of “sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of “open” study design
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3 months: data used -
Outcome assessors blinded for assessment
of recurrent DVT “pre and post-treatment
phlebograms were assessed blindly” - but
no description of blinding of assessors for
PE is provided
Recurrent DVT at 3 months: data used -
see recurrent VTE at 3 months
PE - excluding PE found at autopsy: data
used - see recurrent VTE at 3 months
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants (out of 149) were withdrawn
from the trial
Reasons for withdrawals are clearly pre-
sented:
UFH group - 1 patient had a recent history
of DVT; 1 patient was diagnosed with an-
tithrombin III deﬁciency and 1 patient de-
velopedmajor bleeding andwaswithdrawn
from the study; however, their results did
appear in the ﬁnal analysis
During follow-up 1 patient from the UFH
group died from renal failure
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Lopaciuk 1992 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
Peternel 2002
Methods Study design: open, randomised controlled trial
Duration of intervention: to INR target
Duration of follow-up: 7 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute proximal DVT
Country: Slovenia
Number of study centres: 1
Setting: inpatients
Number: 59 (SC UFH 28; SC LMWH 31)
Age (mean ± SD): SC UFH 68 ± 13 years; SC LMWH 69 ±14 years
Sex (M/F): SC UFH 15/13; SC LMWH 17/14
Inclusion criteria: proximal DVT diagnosed by ultrasound duplex
Exclusion criteria: anticoagulant treatment with heparin or coumarins in the period of
10 days before admission, clinically signiﬁcant pulmonary embolism or pregnancy
Diagnostic criteria: ultrasound duplex
Interventions Intervention (route, total dose/day, frequency): bolus IV UFH, followed by SC UFH
twice daily or TID, aPTT adjusted + warfarin
Control (route, total dose/day, frequency): SC LMWH 200 IU/kg 4 times daily +
warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: major bleeding, death, aPTT, haemostatic markers (F1+2, TAT, D-dimer)
Notes Stated aim of the study: to compare these markers in the acute phase of DVT dur-
ing treatment either with subcutaneous aPTT-adjusted UFH or with weight-adjusted
LMWH in order to estimate control of haemostatic system activation during both regi-
mens
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States random but no description of ran-
domisation method provided
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
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Peternel 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different numbers of injections at different
times - probably prevented adequate blind-
ing
UFH - 1 bolus of heparin given intra-
venously followed by 2-3 subcutaneous in-
jections daily
LWMH - 1 subcutaneous injection daily
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3 months: NA
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: NA
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
High risk Many of the 59 participants were with-
drawn from the study; however, exact num-
bers withdrawn and fromwhich group they
were withdrawn are not presented in the
paper
Reasons for withdrawal are also not clearly
identiﬁed - the paper does state that 2 par-
ticipants died and other participants were
withdrawn when INR > 2 for 2 days; how-
ever, if all participants were withdrawn for
this reason is unclear
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
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Pini 1990
Methods Study design: open randomised controlled trial
Duration of intervention: 7 days
Duration of follow-up: 7 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute DVT
Country: Italy
Number of study centres: 1
Setting: inpatients
Number: 271(SC UFH 138; IV UFH 133)
Age mean (range): SC UFH 63.4 (16 to 87) years; IV UFH 60.9 (11 to 86) years
Sex (M/F): SC UFH 83/55; IV UFH 72/61
Inclusion criteria: acute DVT diagnosed with strain-gauge plethysmography or venog-
raphy
Exclusion criteria: bleedingdisorder, abnormal results in haemostatic function screening
tests, active peptic disease, on heparin treatment + acenocoumarol
Diagnostic criteria: plethysmography or venography in diagnosis not concluded
Interventions Intervention (route, total dose/day, frequency): SC UFH (calcium heparin) 250 U/
kg twice daily + acenocoumarol
Control (route, total dose/day, frequency): IV UFH (sodium heparin bolus) followed
by continuous IV UFH 500 U/Kg/day + acenocoumarol
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, PE, death, bleeding
Notes Stated aim of the study: to compare IV and SC heparin for acute DVT in a large
population study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were assigned by computer-gen-
erated random numbers”
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods of heparin administra-
tion - intravenous compared to subcuta-
neous - probably prevented adequate blind-
ing
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Pini 1990 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
High risk Number of participants (out of 271) who
were withdrawn from the study is not pre-
sented
The study states that 23 participants were
reported as not undergoing strain gauge
plethysmography (SGP) but which group
they came from is omitted as is weather any
other participants were withdrawn - as only
a subset of participants (251) underwent
SGP - is unclear
4 participants in the SC group died (1 from
PE and1 fromcerebral haemorrhage; 2 par-
ticipants died in the intravenous group 1
from PE and 1 from pulmonary haemor-
rhage
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
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Prandoni 2004
Methods Study design: open randomised controlled trial
Duration of intervention: 5 days to INR
Duration of follow-up: 3 months
Run-in period: NA
Intention-to-treat analysis: yes
Language of publication: English
Participants Who participated: people with acute VTE (DVT + PE)
Number of study centres: 19
Setting: inpatients
Number: 720 (SC UFH 360; SC LMWH 360)
Age (mean ± SD): SC UFH 65.7 ± 15.6 years; SC LMWH 67.0 ± 14.8 years
Sex M/F: SC UFH 158/202; SC LMWH 167/193
Inclusion criteria: people with DVT of the lower extremities and/or PE were eligible
for the study, provided that the suspicion was objectively conﬁrmed
Exclusion criteria: age less than 18 years, pregnancy, contraindications to anticoagulant
treatment, full-dose anticoagulant treatment (either heparin or oral anticoagulants) for
more than 24 h, haemodynamic instability, previous (less than 1 year earlier) episode of
VTE, life expectancy less than 3months, poor compliance, and geographic inaccessibility
for follow-up
Diagnostic criteria: a positive result of at least 1 of the following tests was accepted for
inclusion: ascending phlebography, compression ultrasound of the proximal vein system,
echo colour Doppler scan of the calf vein system in the case of clinical suspicion of DVT,
ventilation-perfusion scanning, spiral computed tomographic scanning, and pulmonary
angiography in the case of clinical suspicion of PE. In the presence of abnormal results
of an ultrasound test of the lower extremities, the diagnosis of PE was also accepted if a
perfusion lung scan was compatible with a high probability of PE when compared with
the chest x-ray
Type of VTE: 601 DVT/119 PE
Interventions Intervention (route, total dose/day, frequency): IV bolus UFH (calcium heparin)
4000-5000 IU followed by SC UFH twice daily, aPTT adjusted + warfarin
Control (route, total dose/day, frequency): SC LMWH85U/kg twice daily + warfarin
Treatment before study: NA
Outcomes Primary outcome: recurrent VTE at 3 month follow-up
Secondary outcomes: recurrentVTEduringheparin treatment, bleedingduring heparin
treatment, death
Notes Stated aim of the study: to assess the value of UFH or LMWH for treating the full
spectrum of patients with VTE, including recurrent VTE and PE
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation … was performed with a
computer algorithm”
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Prandoni 2004 (Continued)
Allocation concealment (selection bias) Low risk Use of a “24-hour telephone service that
recorded patient information before disclo-
sure of the treatment assigned”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Use of an open study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data used
Minor bleeding: data used
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 0 participants (out of 720) were withdrawn
from the study
“[N]o patients were lost to follow up”
“We…ensured follow upwas complete for
all randomised patients”
During follow-up 24 participants died: In
the UFH group 12 participants died (3
from PE and 1 from haemorrhage); in the
LMWHgroup12participants died (4 from
PE)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No evidence of other biases
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Walker 1987
Methods Study design: open randomised controlled trial
Duration of intervention: 14 days
Duration of follow-up: 14 days
Run-in period: NA
Intention-to-treat analysis: no
Language of publication: English
Participants Who participated: people with acute lower limb DVT
Country: UK
Number of study centres: 5
Setting: inpatients
Number: 100 (SC UFH 50; IV continuous UFH 50)
Age (mean ± SD): SC UFH M 61 ± 11 years, F 63 ± 16 years; IV continuous UFH M
60 ± 14 years, F 63 ±15 years
Sex (M/F): SC UFH 25/25; IV continuous UFH 28/22
Inclusion criteria: people with DVT of the legs (calf + proximal), phlebography proven,
with a thrombus > 5 cm
Exclusion criteria: PE or occlusive thrombus
Diagnostic criteria: phlebography
Interventions Intervention (route, total dose/day, frequency): SC UFH (calcium heparin) 250 U/
kg, aPTT adjusted + warfarin
Control (route, total dose/day, frequency): IV continuous UFH (sodium heparin)
aPTT adjusted + warfarin
Treatment before study: NA
Outcomes Outcomes not speciﬁed as primary or secondary
Outcomes: DVT extension, injection site pain, PE, haemoglobin, platelets, aPTT
Notes Stated aim of the study: to compare the efﬁcacy and safety of SC versus IV heparin for
leg DVT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[T]he randomisation code was drafted us-
ing a standard random number table”
Allocation concealment (selection bias) Low risk “[P]atient allocations were taken from
sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No description of blinding provided
Different methods of heparin administra-
tion - intravenous compared to subcuta-
neous - probably prevented adequate blind-
ing
57Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Walker 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcomes requiring blinding
Recurrent VTE at 3months: data used - no
description of blinding outcome assessors
Recurrent DVT at 3 months: NA
PE - excluding PE found at autopsy: data
used - no description of blinding outcome
assessors
Incidence of heparin-induced thrombocy-
topenia: NA
Incidence of asymptomatic recurrent VTE
at 3 months: NA
Quality of life: NA
Outcomes not requiring blinding
Major bleeding: data not used - not meet-
ing ISTH deﬁnition
Minor bleeding: data not used - not meet-
ing deﬁnition of minor bleeding
VTE-related mortality: data used
All-cause mortality: data used
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 participants (out of 100) were withdrawn
from the study, reasons for withdrawals are
clearly presented:
Intravenous group - 3 participants were ex-
cluded due to “technically unsatisfactory”
phlebograms
Subcutaneous group - 1patient died during
the course of the study
Selective reporting (reporting bias) Low risk The paper states that haemoglobin concen-
tration; packed red cell count and platelet
count were estimated on days 1,7,14 but
no results are presented for these measure-
ments. Nevertheless these were not out-
comes of our review and therefore the study
was judged to be at low risk of reporting
bias
Other bias Low risk No evidence of other biases
aPTT: activated partial thromboplastin time;AT: antithrombin;BP: blood pressure; DVT: deep vein thrombosis;INR: international
normalised ratio;ISTH: International Society on Thrombosis and Haemostasis; IU: international units; IV: intravenous; LMWH:
low molecular weight heparin;NA: not applicable; PE: pulmonary embolism; SC: subcutaneous; UFH: unfractionated heparin;US:
ultrasound; VTE: venous thromboembolism.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Fagher 1981 RCT comparing continuous versus intermittent intravenous heparin administration in people diagnosed with
DVT
Glazier 1976 RCT comparing continuous versus intermittent Intravenous heparin administration in people with PE
Gruber 1979 RCT comparing subcutaneous heparin and dextran for the prophylaxis of VTE
Horbach 1996 RCT comparing subcutaneous LMWH versus subcutaneous UFH for the prophylaxis of VTE
Lockner 1986 RCT comparing intravenous UFH versus intravenous LMWH in people diagnosed with DVT
Marchiori 2002 RCT of people diagnosed with superﬁcial vein thrombosis
Monreal 1994 RCT comparing long-term treatment of people with VTE
Nakamura 2010 RCT comparing intravenous UFH versus LMWH in people diagnosed with PE
NCT01956955 RCT comparing UFH versus LMWH plus thrombolytic treatment in people diagnosed with PE
Quiros 2001 RCT comparing intravenous UFH versus intravenous LMWH in people diagnosed with DVT
Riess 2014 RCT comparing intravenous UFH versus LMWH in people diagnosed with PE
Rodgers 1999 RCT comparing intravenous UFH versus LMWH in people diagnosed with cancer-associated DVT
Romera 2009 RCT comparing LMWH versus VKA in people diagnosed with DVT
Ucar 2015 RCT comparing UFH versus LMWH plus thrombolytic treatment in people diagnosed with PE
Van Doormaal 2009 RCT comparing LMWH only in cancer-related VTE
Van Doormaal 2010 RCT comparing LMWH only in cancer-related DVT
DVT: deep vein thrombosis; LMWH: low molecular weight heparin; PE: pulmonary embolism; RCT: randomised controlled trial;
UFH: unfractionated heparin; VKA: vitamin K antagonist; VTE: venous thromboembolism.
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D A T A A N D A N A L Y S E S
Comparison 1. Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic recurrent VTE at
3 months
8 965 Odds Ratio (M-H, Fixed, 95% CI) 1.66 [0.89, 3.10]
1.1 DVT with/without PE 8 965 Odds Ratio (M-H, Fixed, 95% CI) 1.66 [0.89, 3.10]
2 Symptomatic recurrent DVT at
3 months
1 115 Odds Ratio (M-H, Fixed, 95% CI) 3.29 [0.64, 17.06]
2.1 DVT with/without PE 1 115 Odds Ratio (M-H, Fixed, 95% CI) 3.29 [0.64, 17.06]
3 PE at 3 months 9 1161 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.73, 2.84]
3.1 DVT with/without PE 9 1161 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.73, 2.84]
4 VTE-related mortality at 3
months
9 1168 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.20, 4.88]
4.1 DVT with/without PE 9 1168 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.20, 4.88]
5 Major bleeding 4 583 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.42, 1.97]
5.1 DVT with/without PE 4 583 Odds Ratio (M-H, Fixed, 95% CI) 0.91 [0.42, 1.97]
6 All-cause mortality 8 972 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [0.67, 4.51]
6.1 DVT with/without PE 8 972 Odds Ratio (M-H, Fixed, 95% CI) 1.74 [0.67, 4.51]
7 Treatment related morbidity -
minor bleeding
5 779 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.33, 1.20]
7.1 DVT with/without PE 5 779 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.33, 1.20]
Comparison 2. Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic recurrent VTE at
3 months
5 2156 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.63, 1.63]
1.1 DVT with/without PE 3 1954 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.57, 1.56]
1.2 DVT without PE 2 202 Odds Ratio (M-H, Fixed, 95% CI) 2.12 [0.38, 11.84]
2 Symptomatic recurrent DVT at
3 months
3 1566 Odds Ratio (M-H, Fixed, 95% CI) 1.38 [0.73, 2.63]
2.1 DVT with/without PE 2 1420 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.65, 2.46]
2.2 DVT without PE 1 146 Odds Ratio (M-H, Fixed, 95% CI) 5.28 [0.25, 111.99]
3 PE at 3 months 5 1819 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.36, 1.96]
3.1 DVT with/without PE 2 1420 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.31, 2.04]
3.2 DVT without PE 3 399 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.14, 7.63]
4 VTE-related mortality at 3
months
8 2469 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.17, 1.67]
4.1 DVT with/without PE 4 2016 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.17, 1.67]
4.2 DVT without PE 4 453 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Major bleeding 5 2300 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.43, 1.20]
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5.1 DVT with/without PE 3 1957 Odds Ratio (M-H, Fixed, 95% CI) 0.69 [0.41, 1.16]
5.2 DVT without PE 2 343 Odds Ratio (M-H, Fixed, 95% CI) 3.13 [0.13, 78.00]
6 All-cause mortality 7 2272 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.50, 1.07]
6.1 DVT with/without PE 4 2016 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.48, 1.05]
6.2 DVT without PE 3 256 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.22, 13.26]
7 Treatment related morbidity -
minor bleeding
5 2300 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.71, 1.37]
7.1 DVT with/without PE 3 1957 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.69, 1.43]
7.2 DVT without PE 2 343 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.44, 2.05]
8 Treatment related morbidity -
HIT
3 1954 Odds Ratio (M-H, Fixed, 95% CI) 1.52 [0.25, 9.14]
8.1 DVT with/without PE 3 1954 Odds Ratio (M-H, Fixed, 95% CI) 1.52 [0.25, 9.14]
Comparison 3. Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large
studies)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic recurrent VTE at
3 months
3 736 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.29, 2.16]
2 Symptomatic recurrent DVT at
3 months
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 PE at 3 months 3 399 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.14, 7.63]
4 VTE-related mortality at 3
months
6 1049 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.06, 16.13]
5 Major bleeding 3 880 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.41, 2.09]
6 All-cause mortality 5 852 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.32, 1.03]
7 Treatment-related morbidity 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Minor bleeding 3 880 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.60, 1.30]
7.2 Heparin-induced
thrombocytopenia
1 534 Odds Ratio (M-H, Fixed, 95% CI) 2.05 [0.19, 22.78]
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Analysis 1.1. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 1 Symptomatic recurrent VTE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 1 Symptomatic recurrent VTE at 3 months
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Andersson 1982 1/72 1/69 6.5 % 0.96 [ 0.06, 15.62 ]
Bentley 1980 1/50 1/50 6.3 % 1.00 [ 0.06, 16.44 ]
Doyle 1987 5/47 5/49 28.2 % 1.05 [ 0.28, 3.88 ]
Hull 1986 11/57 3/58 15.5 % 4.38 [ 1.15, 16.66 ]
Kra¨henbu¨hl 1979 1/23 1/25 5.9 % 1.09 [ 0.06, 18.51 ]
Lopaciuk 1990 2/48 1/46 6.3 % 1.96 [ 0.17, 22.34 ]
Pini 1990 4/138 2/133 12.7 % 1.96 [ 0.35, 10.86 ]
Walker 1987 2/50 3/50 18.6 % 0.65 [ 0.10, 4.09 ]
Total (95% CI) 485 480 100.0 % 1.66 [ 0.89, 3.10 ]
Total events: 27 (SC UFH), 17 (IV UFH)
Heterogeneity: Chi2 = 3.91, df = 7 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours SC UFH Favours IV UFH
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Analysis 1.2. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 2 Symptomatic recurrent DVT at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 2 Symptomatic recurrent DVT at 3 months
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Hull 1986 6/57 2/58 100.0 % 3.29 [ 0.64, 17.06 ]
Total (95% CI) 57 58 100.0 % 3.29 [ 0.64, 17.06 ]
Total events: 6 (SC UFH), 2 (IV UFH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours SC UFH Favours IV UFH
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Analysis 1.3. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 3 PE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 3 PE at 3 months
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Andersson 1982 1/72 1/69 7.2 % 0.96 [ 0.06, 15.62 ]
Belcaro 1999 0/99 0/97 Not estimable
Bentley 1980 1/50 1/50 7.0 % 1.00 [ 0.06, 16.44 ]
Doyle 1987 5/47 5/49 31.2 % 1.05 [ 0.28, 3.88 ]
Hull 1986 5/57 1/58 6.5 % 5.48 [ 0.62, 48.47 ]
Kra¨henbu¨hl 1979 1/23 1/25 6.5 % 1.09 [ 0.06, 18.51 ]
Lopaciuk 1990 2/48 1/46 7.0 % 1.96 [ 0.17, 22.34 ]
Pini 1990 4/138 2/133 14.1 % 1.96 [ 0.35, 10.86 ]
Walker 1987 2/50 3/50 20.5 % 0.65 [ 0.10, 4.09 ]
Total (95% CI) 584 577 100.0 % 1.44 [ 0.73, 2.84 ]
Total events: 21 (SC UFH), 15 (IV UFH)
Heterogeneity: Chi2 = 2.75, df = 7 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours SC UFH Favours IV UFH
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Analysis 1.4. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 4 VTE-related mortality at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 4 VTE-related mortality at 3 months
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Andersson 1982 0/72 0/69 Not estimable
Belcaro 1999 0/99 0/97 Not estimable
Bentley 1980 0/50 0/50 Not estimable
Doyle 1987 0/51 0/52 Not estimable
Hull 1986 1/57 0/58 16.0 % 3.11 [ 0.12, 77.85 ]
Kra¨henbu¨hl 1979 0/23 0/25 Not estimable
Lopaciuk 1990 0/48 1/46 50.4 % 0.31 [ 0.01, 7.87 ]
Pini 1990 1/138 1/133 33.6 % 0.96 [ 0.06, 15.56 ]
Walker 1987 0/50 0/50 Not estimable
Total (95% CI) 588 580 100.0 % 0.98 [ 0.20, 4.88 ]
Total events: 2 (SC UFH), 2 (IV UFH)
Heterogeneity: Chi2 = 0.97, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 5 Major bleeding.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 5 Major bleeding
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Doyle 1987 4/51 2/52 13.5 % 2.13 [ 0.37, 12.16 ]
Hull 1986 2/57 2/58 14.1 % 1.02 [ 0.14, 7.49 ]
Lopaciuk 1990 2/48 1/46 7.2 % 1.96 [ 0.17, 22.34 ]
Pini 1990 5/138 9/133 65.2 % 0.52 [ 0.17, 1.59 ]
Total (95% CI) 294 289 100.0 % 0.91 [ 0.42, 1.97 ]
Total events: 13 (SC UFH), 14 (IV UFH)
Heterogeneity: Chi2 = 2.28, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 6 All-cause mortality.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 6 All-cause mortality
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Andersson 1982 0/72 0/69 Not estimable
Bentley 1980 0/50 0/50 Not estimable
Doyle 1987 0/51 0/52 Not estimable
Hull 1986 6/57 3/58 40.1 % 2.16 [ 0.51, 9.08 ]
Kra¨henbu¨hl 1979 0/23 0/25 Not estimable
Lopaciuk 1990 0/48 1/46 22.8 % 0.31 [ 0.01, 7.87 ]
Pini 1990 4/138 2/133 29.8 % 1.96 [ 0.35, 10.86 ]
Walker 1987 1/50 0/50 7.3 % 3.06 [ 0.12, 76.95 ]
Total (95% CI) 489 483 100.0 % 1.74 [ 0.67, 4.51 ]
Total events: 11 (SC UFH), 6 (IV UFH)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Subcutaneous unfractionated heparin versus intravenous unfractionated
heparin, Outcome 7 Treatment related morbidity - minor bleeding.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 1 Subcutaneous unfractionated heparin versus intravenous unfractionated heparin
Outcome: 7 Treatment related morbidity - minor bleeding
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Belcaro 1999 1/99 4/97 17.2 % 0.24 [ 0.03, 2.16 ]
Doyle 1987 1/51 3/52 12.5 % 0.33 [ 0.03, 3.25 ]
Hull 1986 1/57 2/58 8.4 % 0.50 [ 0.04, 5.67 ]
Lopaciuk 1990 10/48 13/46 45.1 % 0.67 [ 0.26, 1.72 ]
Pini 1990 5/138 4/133 16.9 % 1.21 [ 0.32, 4.62 ]
Total (95% CI) 393 386 100.0 % 0.63 [ 0.33, 1.20 ]
Total events: 18 (SC UFH), 26 (IV UFH)
Heterogeneity: Chi2 = 2.04, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 1 Symptomatic recurrent VTE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 1 Symptomatic recurrent VTE at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 13/348 12/352 34.1 % 1.10 [ 0.49, 2.44 ]
Leizorovicz 2011 3/264 7/270 20.3 % 0.43 [ 0.11, 1.69 ]
Prandoni 2004 15/360 14/360 39.9 % 1.07 [ 0.51, 2.26 ]
Subtotal (95% CI) 972 982 94.4 % 0.95 [ 0.57, 1.56 ]
Total events: 31 (SC UFH), 33 (LMWH)
Heterogeneity: Chi2 = 1.52, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
2 DVT without PE
Holm 1986 0/27 1/29 4.2 % 0.35 [ 0.01, 8.85 ]
Lopaciuk 1992 3/72 0/74 1.4 % 7.50 [ 0.38, 147.90 ]
Subtotal (95% CI) 99 103 5.6 % 2.12 [ 0.38, 11.84 ]
Total events: 3 (SC UFH), 1 (LMWH)
Heterogeneity: Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1071 1085 100.0 % 1.01 [ 0.63, 1.63 ]
Total events: 34 (SC UFH), 34 (LMWH)
Heterogeneity: Chi2 = 3.72, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
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Analysis 2.2. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 2 Symptomatic recurrent DVT at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 2 Symptomatic recurrent DVT at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 11/348 8/352 48.2 % 1.40 [ 0.56, 3.53 ]
Prandoni 2004 9/360 8/360 48.8 % 1.13 [ 0.43, 2.96 ]
Subtotal (95% CI) 708 712 97.0 % 1.27 [ 0.65, 2.46 ]
Total events: 20 (SC UFH), 16 (LMWH)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
2 DVT without PE
Lopaciuk 1992 2/72 0/74 3.0 % 5.28 [ 0.25, 111.99 ]
Subtotal (95% CI) 72 74 3.0 % 5.28 [ 0.25, 111.99 ]
Total events: 2 (SC UFH), 0 (LMWH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Total (95% CI) 780 786 100.0 % 1.38 [ 0.73, 2.63 ]
Total events: 22 (SC UFH), 16 (LMWH)
Heterogeneity: Chi2 = 0.91, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.80, df = 1 (P = 0.37), I2 =0.0%
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Analysis 2.3. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 3 PE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 3 PE at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 2/348 4/352 33.6 % 0.50 [ 0.09, 2.76 ]
Prandoni 2004 6/360 6/360 50.2 % 1.00 [ 0.32, 3.13 ]
Subtotal (95% CI) 708 712 83.8 % 0.80 [ 0.31, 2.04 ]
Total events: 8 (SC UFH), 10 (LMWH)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 DVT without PE
Belcaro 1999 0/99 0/98 Not estimable
Holm 1986 0/27 1/29 12.1 % 0.35 [ 0.01, 8.85 ]
Lopaciuk 1992 1/72 0/74 4.1 % 3.13 [ 0.13, 78.00 ]
Subtotal (95% CI) 198 201 16.2 % 1.05 [ 0.14, 7.63 ]
Total events: 1 (SC UFH), 1 (LMWH)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 906 913 100.0 % 0.84 [ 0.36, 1.96 ]
Total events: 9 (SC UFH), 11 (LMWH)
Heterogeneity: Chi2 = 1.37, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 2.4. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 4 VTE-related mortality at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 4 VTE-related mortality at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Faivre 1987 0/29 0/30 Not estimable
Kearon 2006 0/348 3/352 41.2 % 0.14 [ 0.01, 2.78 ]
Leizorovicz 2011 1/268 1/269 11.8 % 1.00 [ 0.06, 16.13 ]
Prandoni 2004 3/360 4/360 47.0 % 0.75 [ 0.17, 3.37 ]
Subtotal (95% CI) 1005 1011 100.0 % 0.53 [ 0.17, 1.67 ]
Total events: 4 (SC UFH), 8 (LMWH)
Heterogeneity: Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
2 DVT without PE
Belcaro 1999 0/99 0/98 Not estimable
Holm 1986 0/27 0/29 Not estimable
Lopaciuk 1992 0/72 0/74 Not estimable
Peternel 2002 0/27 0/27 Not estimable
Subtotal (95% CI) 225 228 Not estimable
Total events: 0 (SC UFH), 0 (LMWH)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1230 1239 100.0 % 0.53 [ 0.17, 1.67 ]
Total events: 4 (SC UFH), 8 (LMWH)
Heterogeneity: Chi2 = 1.15, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 5 Major bleeding.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 5 Major bleeding
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 10/348 17/352 46.5 % 0.58 [ 0.26, 1.29 ]
Leizorovicz 2011 10/268 12/269 32.6 % 0.83 [ 0.35, 1.96 ]
Prandoni 2004 5/360 7/360 19.5 % 0.71 [ 0.22, 2.26 ]
Subtotal (95% CI) 976 981 98.6 % 0.69 [ 0.41, 1.16 ]
Total events: 25 (SC UFH), 36 (LMWH)
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
2 DVT without PE
Belcaro 1999 0/99 0/98 Not estimable
Lopaciuk 1992 1/72 0/74 1.4 % 3.13 [ 0.13, 78.00 ]
Subtotal (95% CI) 171 172 1.4 % 3.13 [ 0.13, 78.00 ]
Total events: 1 (SC UFH), 0 (LMWH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 1147 1153 100.0 % 0.72 [ 0.43, 1.20 ]
Total events: 26 (SC UFH), 36 (LMWH)
Heterogeneity: Chi2 = 1.18, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 0.83, df = 1 (P = 0.36), I2 =0.0%
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Analysis 2.6. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 6 All-cause mortality.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 6 All-cause mortality
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Faivre 1987 0/29 0/30 Not estimable
Kearon 2006 18/348 22/352 33.0 % 0.82 [ 0.43, 1.55 ]
Leizorovicz 2011 17/268 31/269 46.2 % 0.52 [ 0.28, 0.96 ]
Prandoni 2004 12/360 12/360 18.5 % 1.00 [ 0.44, 2.26 ]
Subtotal (95% CI) 1005 1011 97.7 % 0.71 [ 0.48, 1.05 ]
Total events: 47 (SC UFH), 65 (LMWH)
Heterogeneity: Chi2 = 1.84, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
2 DVT without PE
Holm 1986 0/27 0/29 Not estimable
Lopaciuk 1992 1/72 0/74 0.8 % 3.13 [ 0.13, 78.00 ]
Peternel 2002 1/27 1/27 1.5 % 1.00 [ 0.06, 16.85 ]
Subtotal (95% CI) 126 130 2.3 % 1.71 [ 0.22, 13.26 ]
Total events: 2 (SC UFH), 1 (LMWH)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 1131 1141 100.0 % 0.73 [ 0.50, 1.07 ]
Total events: 49 (SC UFH), 66 (LMWH)
Heterogeneity: Chi2 = 2.69, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 2.7. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 7 Treatment related morbidity - minor bleeding.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 7 Treatment related morbidity - minor bleeding
Study or subgroup SC UFH IV UFH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 23/348 18/352 23.5 % 1.31 [ 0.70, 2.48 ]
Leizorovicz 2011 43/268 49/269 57.8 % 0.86 [ 0.55, 1.35 ]
Prandoni 2004 0/360 0/360 Not estimable
Subtotal (95% CI) 976 981 81.3 % 0.99 [ 0.69, 1.43 ]
Total events: 66 (SC UFH), 67 (IV UFH)
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 0.06 (P = 0.96)
2 DVT without PE
Belcaro 1999 1/99 3/98 4.2 % 0.32 [ 0.03, 3.16 ]
Lopaciuk 1992 14/72 13/74 14.5 % 1.13 [ 0.49, 2.61 ]
Subtotal (95% CI) 171 172 18.7 % 0.95 [ 0.44, 2.05 ]
Total events: 15 (SC UFH), 16 (IV UFH)
Heterogeneity: Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 1147 1153 100.0 % 0.98 [ 0.71, 1.37 ]
Total events: 81 (SC UFH), 83 (IV UFH)
Heterogeneity: Chi2 = 2.17, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 2.8. Comparison 2 Subcutaneous unfractionated heparin versus low molecular weight heparin,
Outcome 8 Treatment related morbidity - HIT.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 2 Subcutaneous unfractionated heparin versus low molecular weight heparin
Outcome: 8 Treatment related morbidity - HIT
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 DVT with/without PE
Kearon 2006 0/348 0/352 Not estimable
Leizorovicz 2011 2/264 1/270 49.6 % 2.05 [ 0.19, 22.78 ]
Prandoni 2004 1/360 1/360 50.4 % 1.00 [ 0.06, 16.05 ]
Total (95% CI) 972 982 100.0 % 1.52 [ 0.25, 9.14 ]
Total events: 3 (SC UFH), 2 (LMWH)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 1 Symptomatic recurrent VTE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 1 Symptomatic recurrent VTE at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Holm 1986 0/27 1/29 16.3 % 0.35 [ 0.01, 8.85 ]
Leizorovicz 2011 3/264 7/270 78.3 % 0.43 [ 0.11, 1.69 ]
Lopaciuk 1992 3/72 0/74 5.4 % 7.50 [ 0.38, 147.90 ]
Total (95% CI) 363 373 100.0 % 0.80 [ 0.29, 2.16 ]
Total events: 6 (SC UFH), 8 (LMWH)
Heterogeneity: Chi2 = 3.21, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 2 Symptomatic recurrent DVT at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 2 Symptomatic recurrent DVT at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lopaciuk 1992 2/72 0/74 5.28 [ 0.25, 111.99 ]
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Analysis 3.3. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 3 PE at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 3 PE at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belcaro 1999 0/99 0/98 Not estimable
Holm 1986 0/27 1/29 74.6 % 0.35 [ 0.01, 8.85 ]
Lopaciuk 1992 1/72 0/74 25.4 % 3.13 [ 0.13, 78.00 ]
Total (95% CI) 198 201 100.0 % 1.05 [ 0.14, 7.63 ]
Total events: 1 (SC UFH), 1 (LMWH)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 4 VTE-related mortality at 3 months.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 4 VTE-related mortality at 3 months
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belcaro 1999 0/99 0/98 Not estimable
Faivre 1987 0/29 0/30 Not estimable
Holm 1986 0/27 0/29 Not estimable
Leizorovicz 2011 1/268 1/269 100.0 % 1.00 [ 0.06, 16.13 ]
Lopaciuk 1992 0/72 0/74 Not estimable
Peternel 2002 0/27 0/27 Not estimable
Total (95% CI) 522 527 100.0 % 1.00 [ 0.06, 16.13 ]
Total events: 1 (SC UFH), 1 (LMWH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 5 Major bleeding.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 5 Major bleeding
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Belcaro 1999 0/99 0/98 Not estimable
Leizorovicz 2011 10/268 12/269 96.0 % 0.83 [ 0.35, 1.96 ]
Lopaciuk 1992 1/72 0/74 4.0 % 3.13 [ 0.13, 78.00 ]
Total (95% CI) 439 441 100.0 % 0.92 [ 0.41, 2.09 ]
Total events: 11 (SC UFH), 12 (LMWH)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 6 All-cause mortality.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 6 All-cause mortality
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Faivre 1987 0/29 0/30 Not estimable
Holm 1986 0/27 0/29 Not estimable
Leizorovicz 2011 17/268 31/269 95.2 % 0.52 [ 0.28, 0.96 ]
Lopaciuk 1992 1/72 0/74 1.6 % 3.13 [ 0.13, 78.00 ]
Peternel 2002 1/27 1/27 3.2 % 1.00 [ 0.06, 16.85 ]
Total (95% CI) 423 429 100.0 % 0.58 [ 0.32, 1.03 ]
Total events: 19 (SC UFH), 32 (LMWH)
Heterogeneity: Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.85 (P = 0.065)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours SC UFH Favours LMWH
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Analysis 3.7. Comparison 3 Subcutaneous unfractionated heparin versus low molecular weight heparin
(excluding large studies), Outcome 7 Treatment-related morbidity.
Review: Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Comparison: 3 Subcutaneous unfractionated heparin versus low molecular weight heparin (excluding large studies)
Outcome: 7 Treatment-related morbidity
Study or subgroup SC UFH LMWH Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Minor bleeding
Belcaro 1999 1/99 3/98 5.5 % 0.32 [ 0.03, 3.16 ]
Leizorovicz 2011 43/268 49/269 75.5 % 0.86 [ 0.55, 1.35 ]
Lopaciuk 1992 14/72 13/74 19.0 % 1.13 [ 0.49, 2.61 ]
Subtotal (95% CI) 439 441 100.0 % 0.88 [ 0.60, 1.30 ]
Total events: 58 (SC UFH), 65 (LMWH)
Heterogeneity: Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Heparin-induced thrombocytopenia
Leizorovicz 2011 2/264 1/270 100.0 % 2.05 [ 0.19, 22.78 ]
Subtotal (95% CI) 264 270 100.0 % 2.05 [ 0.19, 22.78 ]
Total events: 2 (SC UFH), 1 (LMWH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
0.001 0.01 0.1 1 10 100 1000
Favours SC UFH Favours LMWH
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MESH DESCRIPTOR Thrombosis 1238
#2 MESH DESCRIPTOR Thromboembolism 899
#3 MESH DESCRIPTOR Venous Thromboembolism 242
#4 MESHDESCRIPTOR Venous Thrombosis EXPLODE ALL
TREES
2005
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(Continued)
#5 (thrombus* or thrombopro* or thrombotic* or thrombolic*
or thromboemboli* or thrombos* or embol* or microembol*)
:TI,AB,KY
17662
#6 MESH DESCRIPTOR Pulmonary Embolism EXPLODE
ALL TREES
735
#7 (PE or DVT or VTE):TI,AB,KY 4611
#8 ((vein* or ven*) near thromb*):TI,AB,KY 6276
#9 (blood near3 clot*):TI,AB,KY 2696
#10 (pulmonary near3 clot*):TI,AB,KY 5
#11 (lung near3 clot*):TI,AB,KY 4
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11
22923
#13 MESH DESCRIPTOR Heparin 2794
#14 (unfractionated or UFH):TI,AB,KY 1235
#15 *heparin*:TI,AB,KY 8806
#16 (calciparin* or eparin* or liquaemin or panheprin or multi-
parin* or hepalean or CY216):TI,AB,KY
39
#17 heparinic:TI,AB,KY 1
#18 #13 OR #14 OR #15 OR #16 OR #17 8855
#19 #12 AND #18 4164
Appendix 2. Trial registries searches
Clinicaltrials.gov
97 studies for (thrombosis OR embolism) AND heparin AND randomized AND (subcutaneous OR sc OR s.c)
WHO
32 records for 9 trials found
subcutaneous OR sc OR s.c in title
and
thrombosis OR embolism in condition
and
heparin in intervention
ISRCTN
No results found for Condition: thrombosis OR embolism AND Interventions: heparin AND subcutaneous
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Appendix 3. Additional study information
Study ID Setting (in or
out patient) of
SC administra-
tion
Control Initial IV hep-
arin bolus be-
fore SC admin-
istration?
Vitamin K an-
tagonist
Vitamin K an-
tagonist timing
Dose
adjustment
Andersson 1982 Inpatient IV heparin Yes Warfarin 1-2 days aPTT
Belcaro 1999 Inpatient and
outpatient
IV heparin +
LMWH
No No (SC
extended period)
NA Fixed dose
Bentley 1980 Inpatient IV heparin No Warfarin 3 days aPTT
Doyle 1987 Inpatient IV heparin Yes Warfarin 7 days aPTT
Faivre 1987 Inpatient LMWH No Not stated NA aPTT
Holm 1986 Inpatient LMWH Yes (ﬁrst
24 hours contin-
uous)
Warfarin 1 day AntiXa inhibitor
Hull 1986 Inpatient IV heparin Yes Warfarin 6-7 days aPTT
Kearon 2006 Inpatient and
outpatient
LMWH No Warfarin 1 day Weight adjusted
Krähenbühl
1979
Inpatient IV heparin Yes Unclear NA aPTT
Leizorovicz 2011 Inpatient LMWH Unclear Unclear 1-3 days aPTT
Lopaciuk 1990 Inpatient IV heparin Yes Sintron Unclear aPTT
Lopaciuk 1992 Inpatient LMWH Yes Sintron 7 days aPTT
Peternel 2002 Inpatient LMWH Yes Warfarin 2 days aPTT
Pini 1990 Inpatient IV heparin No Sintron 3 days Unclear
Prandoni 2004 Inpatient LMWH Yes Warfarin 2 days aPTT
Walker 1987 Inpatient IV heparin No Warfarin 7 days aPTT
aPTT: activated partial thromboplastin time; IV: intravenous; LMWH: low molecular weight heparin; NA: not applicable; SC:
subcutaneous.
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WH A T ’ S N E W
Last assessed as up-to-date: 30 November 2016.
Date Event Description
30 November 2016 New search has been performed Searches rerun. One new study included and nine new
studies excluded
30 November 2016 New citation required but conclusions have not
changed
Searches rerun. One new study included and nine
new studies excluded. Review updated using current
Cochrane standards. New authors have taken over this
review
C O N T R I B U T I O N S O F A U T H O R S
JS: selected and assessed the quality of trials for inclusion in this update, extracted and entered data for analyses, and wrote the text of
the review.
LR: selected and assessed the quality of trials for inclusion in this update, extracted and entered data for analyses, and wrote the text of
the review.
D E C L A R A T I O N S O F I N T E R E S T
JS: none known.
LR: none known.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this update, we amended the outcomes of the review to reﬂect current terminology and practice. We redeﬁned the outcome
’treatment-related serious adverse effects, i.e. major bleeding; overall mortality’ as two events, namely ’all-cause mortality’ and ’major
bleeding’. In addition, we used a more comprehensive deﬁnition of bleeding.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Anticoagulants [∗administration & dosage; adverse effects]; Heparin [∗administration & dosage; adverse effects]; Hep-
arin, Low-Molecular-Weight [administration & dosage; adverse effects]; Infusions, Intravenous; Injections, Subcutaneous; Randomized
Controlled Trials as Topic; Recurrence; Venous Thromboembolism [∗drug therapy]; Venous Thrombosis [drug therapy]
MeSH check words
Humans
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